




מדינת ישראל
STATE OF ISRAEL



4

1000/36

Ministry of Justice
Patent Office

משרד המשפטים
לשכת הפטנטים

09/84-36

This is to certify that
annexed hereto is a true
copy of the documents as
originally deposited with
the patent application
of which particulars are
specified on the first page
of the annex.

זאת לתעודה כי
רצופים בזה העתקים
נכונים של המסמכים
שהופקדו לכתחילה
עם הבקשה לפטנט
לפי הפרטים הרשומים
בעמוד הראשון של
הנספח.

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



This

13-11-2000

היום

ממנה של המנהלים

רשם הפטנטים

Commissioner of Patents

נתאשר
Certified

מספר
Number

תאריך:
Date

הוקדם/נדחה:
Ante Post-dated

10-27-196

Application For Patent

אני, (שם המבקש, מענו ולגבי גוף מאגדת מקום התאגדותו)

Compugen Ltd., Israeli Company of 72, Pinchas Rozen St., Tel Aviv 69512, ISRAEL

Right of Law

Owner, by virtue of

(Hebrew)

(באנגלית)

Hereby apply for a patent to be granted to me in respect thereof.

מבקש בזאת כי ינתן לי עליה פטנט

דרישת דין קדימה
Priority Claim

• בקשת חלוקה
Application of Division

• בקשת פטנט מוסף
Appl. for Patent of Addition

מבקשת פטנט
from application

• לבקשה/לפטנט
to Patent/Appl.

No. _____ מ'ס'

No.	to Patent/Appl.	'ממ
-----	-----------------	-----

Dated _____ מיום _____

Dated: _____

P.o.A.:	General
---------	---------

• יפהי כח : כללי

filed in case **P128131**

הוגש בעניין

המען למסירת מסמכים בישראל
Address for Service in Israel

REINHOLD COHN AND PARTNERS

Patent Attorneys

P.O.B. 4060, Tel-Aviv

C. 122052

חתימת המבקש

Signature of Applicant

For the Applicants.

REINHOLD COHN AND PARTNERS

By : —

1999 שנת December בחדש 27 היום
Year of This

לשימוש הלשכה
For Office Use

This form, impressed with the Seal of the Patent Office and indicating the number and date of filing, certifies the filing of the application the particulars of which are set out above.

• מחק את המיות

Delete whatever is inapplicable

1 1

רצפי חומצות גרעין וחומצות אמינו חדשים
Novel nucleic acid and amino acid sequences

Compugen Ltd.

קומפיוגן בע"מ

C. 122052

FIELD OF THE INVENTION

The present invention concerns novel nucleic acid sequences, vectors and host cells containing them, amino acid sequences encoded by said sequences, and antibodies reactive with said amino acid sequences, as well as pharmaceutical
5 compositions comprising any of the above. The present invention further concerns methods for screening for candidate activator or deactivators utilizing said amino acid sequences.

BACKGROUND OF THE INVENTION

Bone morphogenetic proteins (BMPs) are members of the TGS- β super
10 family of peptides which have conserved carboxy-terminal regions containing seven cysteine repeats. Multiple BMPs or osteogenic proteins (OPs) have been described including BMP-2, -3 (or osteogenin), -4 -5 -6 -7 (or OPI) and -8 (or OP2). BMPs are known for their role in embryonic development and differentiation and have also mitogenic properties for skeletal cells inducing the differentiation of
15 mesenchymal cells into osteogenic cells as well as enhancement of the differentiation of osteoblast. They are also known to increase collagen synthesis and inhibit collagenase 3 expression by osteoblast.

Chordin is a secreted glycoprotein with a molecular mass of 120 kD and is synthesized by the Spemann organizer of the amphibian gastrula. Chordin mimics
20 the action of the Spemann organizer which can induce the formation of neural tissue from ectoderm and induce dorsalization of the ventral mesoderm to form muscle. These two activities are opposed (i.e. antagonized) by BMPs and chordin binds and blocks the action of BMP-2 and BMP-4 by preventing receptor binding. It has been postulated that chordin may be expressed by cells of the osteoblastic
25 lineage to limit BMP actions in the osteoblast. This would be a critical function for
a BMP binding protein since excessive BMP-4 has been implicated in pathogenesis

of fibrodysplasia ossificans progressiva. It has been postulated that BMPs can cause induction of noggin and chordin mRNA and protein levels in skeletal cells by transcriptional mechanisms, and in turn these prevent the effect of BMPs in osteoblast in a negative-type feedback. The induction of these proteins by BMPs appears to be a mechanism to limit the BMP effect in bones (Gazzerro *et al.*, *J. Clin. Invest.*, **102**(12):2106-2114 (1998)).

GLOSSARY

In the following description and claims use will be made, at times, with a variety of terms, and the meaning of such terms as they should be construed in accordance with the invention is as follows:

“Chordin like homolog (CLH) nucleic acid sequence” – the sequence shown in any one of SEQ ID NO: 1 to 4, sequences having at least 70% identity to said sequence and fragments of the above sequences being 20 b.p. long. Those sequences are sequences coding for a novel homolog of the known Chordin protein, as well as for variants of the novel homolog produced by alternative splicing.

The sequence shown in SEQ ID NO: 1 is a homolog to the known chordins within the VWFC domain, named after the von-Willebrand factor (VWF) type C repeat, which is found 2-4 times in these multi-domain proteins. The VWFC domain has a length of about 70 amino acids covering 10 well conserved cysteines. The presence of this region in complex-forming proteins leads to the assumption that the VWFC domain might be involved in forming larger protein complexes. The homolog is a part of a longer sequence termed hereinafter *“full sequence”*. The full sequence has three naturally occurring splice variants which are also termed CLH. The first variant (SEQ ID NO: 2) has 3 out of VWFC domains of the known chordin. The protein coded therefrom contains a predicted signal peptide. The second variant (SEQ ID NO: 3) and third variant (SEQ ID NO: 4) contain 3 out of 4 VWFC domains of the known chordin, but is not predicted to contain the signal sequence.

However, the term CLH does not necessarily signify that CLH protein coded by the above sequences (including the variant sequences) has the same or even similar physiological effects as known Chordins, merely that it shows sequence homology with the known Chordin.

5

“Variant” – a sequence produced by alternative splicing of chordin like homolog of SEQ ID NO: 1. These sequences are not merely truncated forms of the full sequence, or modifications of the SEQ ID NO: 1 but rather naturally occurring sequences resulting from various alternative splicings.

10

“Chordin like homology product (CLH product) – also referred at times as the “CLH protein” or “CLH polypeptide” – is an amino acid coded by any one of SEQ ID NOS: 1 to 4. The amino acid sequence may be a peptide, a protein, as well as peptides or proteins having *chemically modified* amino acids (see below) such as a glycopeptide or glycoprotein. An example of an CLH product is shown in any one of SEQ ID NOS: 5 to 8. The term also includes analogues of said sequences in which one or more amino acids has been added, deleted, *substituted* (see below) or *chemically modified* (see below) as well as fragments of this sequence having at least 10 amino acids.

20

“Nucleic acid sequence” – a sequence composed of DNA nucleotides, RNA nucleotides or a combination of both types and may includes natural nucleotides, chemically modified nucleotides and synthetic nucleotides.

25 *“Amino acid sequence”* – a sequence composed of any one of the 20 naturally appearing amino acids, amino acids which have been *chemically modified* (see below), or composed of synthetic amino acids.

“Fragment of CLH product” - a polypeptide which has an amino acid sequence which is the same as part of but not all of the amino acid sequence of the CLH product.

30

"Fragments of CLH nucleic acid sequence" a continuous portion, preferably of about 20 nucleic acid sequences of the CLH nucleic acid sequence.

"Conservative substitution" - refers to the substitution of an amino acid in one
5 class by an amino acid of the same class, where a class is defined by common physicochemical amino acid side chain properties and high substitution frequencies in homologous proteins found in nature, as determined, for example, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix. [Six general classes of amino acid side chains have been categorized and include:
10 Class I (Cys); Class II (Ser, Thr, Pro, Ala, Gly); Class III (Asn, Asp, Gln, Glu); Class IV (His, Arg, Lys); Class V (Ile, Leu, Val, Met); and Class VI (Phe, Tyr, Trp). For example, substitution of an Asp for another class III residue such as Asn, Gln, or Glu, is a conservative substitution.

15 *"Non-conservative substitution"* - refers to the substitution of an amino acid in one class with an amino acid from another class: for example, substitution of an Ala, a class II residue, with a class III residue such as Asp, Asn, Glu, or Gln.

"Chemically modified" - when referring to the product of the invention, means a
20 product (protein) where at least one of its amino acid residues is modified either by natural processes, such as processing or other post-translational modifications, or by chemical modification techniques which are well known in the art. Among the numerous known modifications typical, but not exclusive examples include: acetylation, acylation, amidation, ADP-ribosylation, glycosylation, GPI anchor
25 formation, covalent attachment of a lipid or lipid derivative, methylation, myristylation, pegylation, prenylation, phosphorylation, ubiquitination, or any similar process.

"Biologically active" - refers to the CLH product which have, regulatory or
30 biochemical functions on the same target sites which naturally occurring CLH

influence. for example can bind to the same receptor as the chordin (or to another receptor), can control BMPs expression, and regulate the amount of effective or biologically available BMP. In particular the CLH may have effects in osteoblasts as well as other cells of mesenchymal origin.

5

"Immunologically active" defines the capability of a natural, recombinant or synthetic CLH product, or any fragment thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. Thus, for example, a biologically active fragment of CLH product denotes a
10 fragment which retains some or all of the immunological properties of the CLH product, e.g can bind specific anti-CLH product antibodies or which can elicit an immune response which will generate such antibodies or cause proliferation of specific immune cells which produce CLH.

15 *"Optimal alignment"* - is defined as an alignment giving the highest percent identity score. Such alignment can be performed using a variety of commercially available sequence analysis programs, such as the local alignment program LALIGN using a ktup of 1, default parameters and the default PAM. A preferred alignment is the one performed using the CLUSTAL-W program from
20 MacVector (TM), operated with an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM similarity matrix. If a gap needs to be inserted into a first sequence to optimally align it with a second sequence, the percent identity is calculated using only the residues that are paired with a corresponding amino acid residue (i.e., the calculation does not consider residues in the second
25 sequences that are in the "gap" of the first sequence).

"Having at least X% identity" - with respect to two amino acid or nucleic acid sequence sequences, refers to the percentage of residues that are identical in the two sequences when the sequences are optimally aligned. Thus, 70% amino acid

sequence identity means that 70% of the amino acids in two or more optimally aligned polypeptide sequences are identical.

"Isolated nucleic acid molecule having an CLH nucleic acid sequence" - is a
5 nucleic acid molecule that includes the coding CLH nucleic acid sequence. Said isolated nucleic acid molecule may include the CLH nucleic acid sequence as an independent insert; may include the CLH nucleic acid sequence fused to an additional coding sequences, encoding together a fusion protein in which the CLH coding sequence is the dominant coding sequence (for example, the
10 additional coding sequence may code for a signal peptide); the CLH nucleic acid sequence may be in combination with non-coding sequences, e.g., introns or control elements, such as promoter and terminator elements or 5' and/or 3' untranslated regions, effective for expression of the coding sequence in a suitable host; or may be a vector in which the CLH protein coding sequence is a
15 heterologous.

"Expression vector" - refers to vectors that have the ability to incorporate and express heterologous DNA fragments in a foreign cell. Many prokaryotic and eukaryotic expression vectors are known and/or commercially available.
20 Selection of appropriate expression vectors is within the knowledge of those having skill in the art.

"Deletion" - is a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

25

"Insertion" or "addition" - is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring sequence.

"Substitution" - replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively. As regards amino acid sequences the substitution may be conservative or non- conservative.

5 *"Antibody"* - refers to IgG, IgM, IgD, IgA, and IgG antibody. The definition includes polyclonal antibodies or monoclonal antibodies. This term refers to whole antibodies or fragments of the antibodies comprising the antigen-binding domain of the anti-CLH product antibodies, e.g. antibodies without the Fc portion, single chain antibodies, fragments consisting of essentially only the
10 variable, antigen-binding domain of the antibody, etc.

"Activator" - as used herein, refers to a molecule which mimics the effect of the natural CLH product or at times even increases or prolongs the duration of the biological activity of said product, as compared to that induced by the natural
15 product. The mechanism may be by binding to the same receptor of target moieties to which native CLH binds thus mimicking the activity of CLH; by prolonging the lifetime of the CLH, (for example by decrease of the rate of its degradation) by increasing the activity of the CLH on its target (modulation of expression and amount of BMPs), by increasing the affinity of CLH to moieties
20 which it binds (such as its receptors) etc. Activators may be polypeptides, nucleic acids, carbohydrates, lipids, or derivatives thereof, or any other molecules which can bind to and activate the CLH product.

"Deactivator" or (*"Inhibitor"*) - refers to a molecule which modulates the
25 activity of the CLH product in an opposite manner to that of the activator, by decreasing or shortening the duration of the biological activity of the CLH product. This may be done by blocking the binding of the CLH to its receptor (competitive or non-competitive inhibition), by causing rapid degradation of the CLH, etc. by inhibiting association of the CLH with the effectors which regulate
30 the expression of BMPs, etc. Deactivators may be polypeptides, nucleic acids,

carbohydrates, lipids, or derivatives thereof, or any other molecules which bind to and modulate the activity of said product.

“*Treating a disease*” - refers to administering a therapeutic substance effective
5 to ameliorate symptoms associated with a disease, to lessen the severity or cure the disease, or to prevent the disease from occurring.

“*Detection*” – refers to a method of detection of a disease. This term may refer to detection of a predisposition to a disease.

10

“*Probe*” – the CLH nucleic acid sequence, or a sequence complementary therewith, when used to detect presence of other similar sequences in a sample. The detection is carried out by identification of hybridization complexes between the probe and the assayed sequence. The probe may be attached to a solid support
15 or to a detectable label.

SUMMARY OF THE INVENTION

The present invention is based on the surprising finding that there exist in humans a novel homolog of the chordin protein having a significant homology to the chordin protein, the homolog is a part of a longer sequence termed “*full*
20 *sequence*”. The invention is further based on the surprising finding that there exist three splice variants to the full sequence which variants are naturally occurring sequences produced from the novel homolog through alternative splicing. Both the homolog and the three variants of the full sequence are collectively termed as “*CLH*”.

25 The novel CLH (in SEQ ID NO: 1) is a homolog to the known chordins within the VWFC domain, named after the von-Willebrand factor (VWF) type C repeat, which is found 2-4 times in these multi-domain proteins. The VWF domain has a length of about 70 amino acids covering 10 well conserved cysteines. The presence of this region in complex-forming proteins leads to the assumption

that the VWFC domain might be involved in forming larger protein complexes. The three variants to the full sequence (for which the homolog is a portion) (SEQ ID NO: 2-4) have 3 or 4 VWF type repeats. SEQ ID NO: 2 also has a sequence coding for a signal sequence, while SEQ ID NO: 3 and 4 are predicted not to have
5 such a signal sequence.

Thus the present invention provides by its first aspect, a novel isolated nucleic acid molecule comprising or consisting of the sequence of any one of SEQ ID NO: 1 to SEQ ID NO: 4, fragments of said sequence having at least 20 nucleic acids, or a molecule comprising a sequence having at least 70%, preferably 80%,
10 and most preferably 90% identity to any one of SEQ ID NO:1 to SEQ ID NO: 4.

The present invention further provides a protein or polypeptide comprising or consisting of an amino acid sequence encoded by any of the above nucleic acid sequences, termed herein "*CLH product*", for example, an amino acid sequence having the sequence as depicted in any one of SEQ ID NO: 5 to 8, fragments of the
15 above amino acid sequence having a length of at least 10 amino acids, as well as homologs of the amino acid sequences of any one of SEQ ID NO: 5 to 8 in which one or more of the amino acid residues has been substituted (by conservative or non-conservative substitution) added, deleted, or chemically modified.

The present invention further provides nucleic acid molecule comprising or
20 consisting of a sequence which encodes the above amino acid sequences, (including the fragments and analogs of the amino acid sequences). Due to the degenerative nature of the genetic code, a plurality of alternative nucleic acid sequences, beyond SEQ ID NO:1 to SEQ ID NO: 4, can code for the amino acid sequence of the invention. Those alternative nucleic acid sequences which code for
25 the same amino acid sequences codes by the sequences of SEQ ID NO: 1 to SEQ ID NO: 4 are also an aspect of the of the present invention.

The present invention further provides expression vectors and cloning vectors comprising any of the above nucleic acid sequences, as well as host cells transfected by said vectors.

The present invention still further provides pharmaceutical compositions comprising, as an active ingredient, said nucleic acid molecules, said expression vectors, or said protein or polypeptide.

These pharmaceutical compositions are suitable for the treatment of diseases and pathological conditions, which can be ameliorated, cured or prevented by raising the level of the CLH product. Typically these are diseases which are manifested by non-normal levels of various BMP proteins (which can be higher or lower than normal levels) which can lead to pathological conditions associated with osteoblasts (such as fibrodysplasia ossificans progressiva) or of other tissues of mesenchymal origin. The compositions are intended to restore the BMP levels to normal levels or to restore the effect of existing levels of BMPs to normal or near normal effects.

By a second aspect, the present invention provides a nucleic acid molecule comprising or consisting of a non-coding sequence which is complementary to that of any one of SEQ ID NO: 1 to SEQ ID NO: 4, or complementary to a sequence having at least 70% identity to said sequence or a fragment of said two sequences. The complementary sequence may be a DNA sequence which hybridizes with any one of the sequences of SEQ ID NO: 1 to SEQ ID NO: 4, or hybridizes to a portion of that sequence having a length sufficient to inhibit the transcription of the complementary sequence. The complementary sequence may be a DNA sequence which can be transcribed into an mRNA being an antisense to the mRNA transcribed from any one of SEQ ID NO: 1 to SEQ ID NO: 4 or into an mRNA which is an antisense to a fragment of the mRNA transcribed from any one of SEQ ID NO: 1 to SEQ ID NO: 4 which has a length sufficient to hybridize with the mRNA transcribed from any one of SEQ ID NO: 1 to SEQ ID NO: 4, so as to inhibit its translation. The complementary sequence may also be the mRNA or the fragment of the mRNA itself.

The nucleic acids of the second aspect of the invention may be used for therapeutic or diagnostic applications for example for detection of the expression of CLH in various tissues such as bones and other tissue of mesenchymal origin. In

addition, the ratio between the level of the chordin like homolog of SEQ ID NO: 1 and that of any of the three splice variants of the full sequence from which the homolog of SEQ ID NO: 1 is a part (SEQ ID NO: 2 to 4), or the ratio of each of the splice variants to another splice variant may also be indicative of a plurality of
5 physiological or pathological conditions.

The present invention also provides expression vectors comprising any one of the above defined complementary nucleic acid sequences and host cells transfected with said nucleic acid sequences or vectors, being complementary to those specified in the first aspect of the invention.

10 The invention also provides anti-CLH product antibodies, namely antibodies directed against the CLH product which specifically bind to said CLH product. Said antibodies are useful both for diagnostic and therapeutic purposes. For example said antibody may be as an active ingredient in a pharmaceutical composition as will be explained below.

15 The present invention also provides pharmaceutical compositions comprising, as an active ingredient, the nucleic acid molecules which comprise or consist of said complementary sequences, or of a vector comprising said complementary sequences. The pharmaceutical composition thus provides pharmaceutical compositions comprising, as an active ingredient, said anti-CLH
20 product antibodies.

The pharmaceutical compositions comprising said anti-CLH product antibodies or the nucleic acid molecule comprising said complementary sequence, are suitable for the treatment of diseases and pathological conditions where a therapeutically beneficial effect may be achieved by neutralizing the CLH or
25 decreasing the amount of the CLH product or blocking its binding to its target (for example its receptor), for example, by the neutralizing effect of the antibodies, or by the decrease of the effect of the antisense mRNA in decreasing expression level of the CLH product. Mostly these diseases are manifested by non-normal levels of BMPs in the diseased persons, or by non-normal effect of BMPs (even at regular
30 levels) on their targeting cells. Said non-normal effect is usually higher than normal

levels. may be down-regulated to produce normal levels. by utilizing the pharmaceutical compositions of the invention.

According to the third aspect of the invention the present invention provides methods for detecting the level of the transcript (mRNA) of said CLH product in a body fluid sample, or in a specific tissue sample (notably bone tissue), for example by use of probes comprising or consisting of said coding sequences; as well as methods for detecting levels of expression of said product in tissue, e.g. by the use of antibodies capable of specifically reacting with the above amino acid sequences. Detection of the level of the expression of the CLH of the invention may be indicative of a plurality of physiological or pathological conditions.

The method, according to this latter aspect, for detection of a nucleic acid sequence which encodes the CLH product in a biological sample, comprises the steps of:

- (a) providing a probe comprising at least one of the nucleic acid sequence defined above;
- (b) contacting the biological sample with said probe under conditions allowing hybridization of nucleic acid sequences thereby enabling formation of hybridization complexes;
- (c) detecting hybridization complexes, wherein the presence of the complex indicates the presence of nucleic acid sequence encoding the CLH product in the biological sample.

The amount of hybridization complexes may be determined and calibrated by comparing it to a calibration scale in order to determine the amount of the nucleic acid sequence which enables the CLH product in the sample. The level of each of the variants (SEQ ID NO: 2-4) may be detected and either compared to the level of the homolog (SEQ ID NO: 1) or to the level of other variants, and said ratio may also be indicative to a plurality of pathological or physiological conditions.

By a preferred embodiment the probe is part of a nucleic acid chip used for detection purposes, i.e. the probe is a part of an array of probes each present in a known location on a solid support.

The nucleic acid sequence used in the above method may be a DNA sequence an RNA sequence, etc; it may be a coding or a sequence or a sequence complementary thereto (for respective detection of RNA transcripts or coding-DNA sequences). By quantization of the level of hybridization complexes
5 and calibrating the quantified results it is possible also to detect the level of the transcript in the sample.

Methods for detecting mutations in the region coding for the CLH product are also provided, which may be methods carried-out in a binary fashion, namely merely detecting whether there is any mismatches between the normal CLH nucleic
10 acid sequence and the one present in the sample. or carried-out by specifically detecting the nature and location of the mutation.

The present invention also concerns a method for detecting CLH product both for determining its presence, as well as its level or alterations in its level in a biological sample, comprising the steps of:

- 15 (a) contacting with said biological sample the antibody of the invention, thereby forming an antibody-antigen complex; and
 - (b) detecting said antibody-antigen complex
- wherein the presence of said antibody-antigen complex correlates with the presence of CLH product in said biological sample.

20 The present invention also concerns a method for detecting anti-CLH antibodies in a biological sample comprising the steps of:

- (a) contacting said biological sample with the product of the invention thereby forming an antibody-antigen complex; and
 - (b) detecting said antibody-antigen complex
- 25 wherein the presence of said antibody-antigen complex correlates with the presence of anti-CHL antibody in said biological sample.

In many cases, diseases are detected not by detecting the presence of the protein (product) which caused the disease, but rather by detecting the presence in a biological sample (such as blood or serum) of antibodies against such a product.
30 The method of detecting the presence of anti-CLH antibodies is intended to be used in such case.

The amount of the antibody-antigen complex can be quantitized, in order to determine the level of the CHL-product or the anti-CHL antibodies, as the case may be.

As explained above the level of the product of SEQ ID NO: 5 (of the novel homolog) can be compared to the level of any one of the products of the variants (SEQ ID NOS. 6-8), or the level of the variant products may be compared to each other, and the ratio between the levels may be indicative to a plurality of physiological and pathological conditions. In addition, the indicative ratio may not be the ratio of the proteins themselves but rather the ratio of antibodies against the proteins.

By yet another aspect the invention also provides a method for identifying candidate compounds capable of modulating the activity of CLH product (being either activators or deactivators). The method includes:

- (i) providing a protein or polypeptide comprising an amino acid sequence substantially as depicted in any one of SEQ ID NO: 5 to SEQ ID NO: 8, or a fragment of such a sequence;
- (ii) contacting a candidate compound with said amino acid sequence;
- (iii) comprising the physiological effect of the amino acid sequence in the presence and absence of said candidate compound and selecting those compounds which show a significant effect on said physiological activity.

The activity of the amino acid which should be changed by the modulator (being either the activator or deactivator) may be for example the binding of the CLH product to its receptor, the effect of CLH on BMPs expression or activity. Any modulator which changes such an activity has an infecting potential, as serving as an actuator or deactivator.

The present invention also concerns compounds identified by the above methods described above, which compound may either be an activator of the CLH product or a deactivator thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

5 **Fig. 1** is alignment of the CLH product of SEQ ID NO: 5 to known chordin protein, demonstrating the homology regions within these proteins. The alignment was performed using best-fit of GCG:

Fig. 2a is the alignment of the first splice variant (SEQ ID NO: 6) to the known chordin deposited in the Emb as gi 4808227;

10 **Fig. 2b** is the alignment of the first splice variant (SEQ ID NO: 6) to the known chordin deposited in the Emb under gi 3822218;

Fig. 2c is the alignment of the first splice variant (SEQ ID NO: 6) to the known chordin deposited in the Emb under gi 3800772;

15 **Fig. 3a** is the alignment of the second splice variant (SEQ ID NO: 7) with a known chordin deposited in the Emb under gi 4808227;

Fig. 3b is the alignment of the second splice variant (SEQ ID NO: 7) with a known chordin deposited in the Emb under gi 3822218;

Fig. 4a is the alignment of the third splice variant (SEQ ID NO: 8) with a known chordin deposited in the Emb under gi 4808227;

20 **Fig. 4b** is the alignment of the third splice variant (SEQ ID NO: 8) with a known chordin deposited in the Emb under gi 2731578;

Fig. 4c is the alignment of the third splice variant (SEQ ID NO: 8) with a known chordin deposited in the Emb under gi 2498235;

25 **Fig. 4d** is the alignment of the third splice variant (SEQ ID NO: 8) with a known chordin deposited in the Emb under gi 3822218;

Fig. 5 is multiple alignments of the sequences to several known chordins.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

Example I: CLH - nucleic acid sequence

The nucleic acid sequences of the invention include nucleic acid sequences which encode CLH product and fragments and analogs thereof. The
5 nucleic acid sequences may alternatively be sequences complementary to the above coding sequence, or to a region of said coding sequence. The length of the complementary sequence is sufficient to avoid the expression of the coding sequence. The nucleic acid sequences may be in the form of RNA or in the form of DNA, and include messenger RNA, synthetic RNA and DNA, cDNA, and
10 genomic DNA. The DNA may be double-stranded or single-stranded, and if single-stranded may be the coding strand or the non-coding (anti-sense, complementary) strand. The nucleic acid sequences may also both include dNTPs, rNTPs as well as non naturally occurring sequences. The sequence may also be a part of a hybrid between an amino acid sequence and a nucleic acid
15 sequence.

In a general embodiment, the nucleic acid sequence has at least 70%, preferably 80% or 90% sequence identity with any one of the sequences identified as SEQ ID NO: 1 to SEQ ID NO: 4.

The nucleic acid sequences may include the coding sequence by itself. By
20 another alternative the coding region may be in combination with additional coding sequences, such as those coding for fusion protein or signal peptides, in combination with non-coding sequences, such as introns and control elements, promoter and terminator elements or 5' and/or 3' untranslated regions, effective for expression of the coding sequence in a suitable host, and/or in a vector or host
25 environment in which the CLH nucleic acid sequence is introduced as a heterologous sequence.

The nucleic acid sequences of the present invention may also have the product coding sequence fused in-frame to a marker sequence which allows for purification of the CLH product. The marker sequence may be, for example, a

hexahistidine tag to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., *et al. Cell* 37:767 (1984)).

Also included in the scope of the invention are fragments also referred to herein as oligonucleotides, typically having at least 20 bases, preferably 20-30 bases corresponding to a region of the coding-sequence nucleic acid sequence. The fragments may be used as probes, primers, and when complementary also as antisense agents, and the like, according to known methods.

As indicated above, the nucleic acid sequence may be substantially as depicted in any one of SEQ ID NO: 1 to SEQ ID NO: 4 or fragments thereof or sequences having at least 70%, preferably 70-80%, most preferably 90% identity to the above sequence. Alternatively, due to the degenerative nature of the genetic code, the sequence may be a sequence coding the amino acid sequence of any one of SEQ ID NO: 5 to SEQ ID NO: 8, or fragments or analogs of said amino acid sequence.

A. Preparation of nucleic acid sequences

The nucleic acid sequences may be obtained by screening cDNA libraries using oligonucleotide probes which can hybridize to or PCR-amplify nucleic acid sequences which encode the CLH products disclosed above. cDNA libraries prepared from a variety of tissues are commercially available and procedures for screening and isolating cDNA clones are well-known to those of skill in the art. Such techniques are described in, for example, Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual* (2nd Edition), Cold Spring Harbor Press, Plainview, N.Y. and Ausubel FM *et al.* (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, N.Y.

The nucleic acid sequences may be extended to obtain upstream and downstream sequences such as promoters, regulatory elements, and 5' and 3'

untranslated regions (UTRs). Extension of the available transcript sequence may be performed by numerous methods known to those of skill in the art, such as PCR or primer extension (Sambrook *et al.*, *supra*), or by the RACE method using, for example, the Marathon RACE kit (Clontech, Cat. # K1802-1).

Alternatively, the technique of "restriction-site" PCR (Gobinda *et al.*, *PCR Methods Applic.* 2:318-22, (1993)), which uses universal primers to retrieve flanking sequence adjacent a known locus, may be employed. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. *et al.*, *Nucleic Acids Res.* 16:8186, (1988)). The primers may be designed using OLIGO(R) 4.06 Primer Analysis Software (1992: National Biosciences Inc, Plymouth, Minn.), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C.

The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Capture PCR (Lagerstrom, M. *et al.*, *PCR Methods Applic.* 1:111-19, (1991)) is a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into a flanking part of the DNA molecule before PCR.

Another method which may be used to retrieve flanking sequences is that of Parker, J.D., *et al.*, *Nucleic Acids Res.*, 19:3055-60, (1991)). Additionally, one can use PCR, nested primers and PromoterFinder™ libraries to "walk in" genomic

DNA (PromoterFinder™; Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. Preferred libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they
5 will contain more sequences which contain the 5' and upstream regions of genes.

A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5' nontranslated regulatory region.

The nucleic acid sequences and oligonucleotides of the invention can also
10 be prepared by solid-phase methods, according to known synthetic methods. Typically, fragments of up to about 100 bases are individually synthesized, then joined to form continuous sequences up to several hundred bases.

B. Use of CLH nucleic acid sequence for the production of CLH products
15

In accordance with the present invention, nucleic acid sequences specified above may be used as recombinant DNA molecules that direct the expression of CLH products.

As will be understood by those of skill in the art, it may be advantageous
20 to produce CLH product-encoding nucleotide sequences possessing codons other than those which appear in any one of SEQ ID NO: 1 to SEQ ID NO: 4 which are those which naturally occur in the human genome. Codons preferred by a particular prokaryotic or eukaryotic CLH host (Murray, E. *et al. Nuc Acids Res.*, 17:477-508, (1989)) can be selected, for example, to increase the rate of CLH
25 product expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence.

The nucleic acid sequences of the present invention can be engineered in order to alter a CLH product coding sequence for a variety of reasons, including
30 but not limited to, alterations which modify the cloning, processing and/or

expression of the product. For example, alterations may be introduced using techniques which are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, to change codon preference, to produce splice variants, etc.

5 The present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises
10 regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are also described in Sambrook, *et al.*, (*supra*).

15 The present invention also relates to host cells which are genetically engineered with vectors of the invention, and the production of the product of the invention by recombinant techniques. Host cells are genetically engineered (i.e., transduced, transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may
20 be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the expression of the CLH nucleic acid sequence. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected
25 for expression, and will be apparent to those skilled in the art.

 The nucleic acid sequences of the present invention may be included in any one of a variety of expression vectors for expressing a product. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast
30 plasmids; vectors derived from combinations of plasmids and phage DNA, viral

DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host. The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate
5 restriction endonuclease site(s) by procedures known in the art. Such procedures and related sub-cloning procedures are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate transcription control sequence (promoter) to direct mRNA synthesis.
10 Examples of such promoters include: LTR or SV40 promoter, the *E.coli lac* or *trp* promoter, the phage lambda *PL* promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation, and a transcription terminator. The vector may also include
15 appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E.coli*.

20 The vector containing the appropriate DNA sequence as described above, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. Examples of appropriate expression hosts include: bacterial cells, such as *E.coli*, *Streptomyces*, *Salmonella typhimurium*; fungal cells, such as yeast; insect cells
25 such as *Drosophila* and *Spodoptera Sf9*; animal cells such as CHO, COS, HEK 293 or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein. The invention is not limited by the host cells employed.

In bacterial systems, a number of expression vectors may be selected
30 depending upon the use intended for the CLH product. For example, when large

quantities of CLH product are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as *Bluescript*(R) (Stratagene), in which the
5 CLH polypeptide coding sequence may be ligated into the vector in-frame with sequences for the amino-terminal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced: *pIN* vectors (Van Heeke & Schuster *J. Biol. Chem.* **264**:5503-5509, (1989)); *pET* vectors (Novagen, Madison WI); and the like.

10 In the yeast *Saccharomyces cerevisiae* a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel *et al. (supra)* and Grant *et al.*, (*Methods in Enzymology* **153**:516-544, (1987)).

In cases where plant expression vectors are used, the expression of a
15 sequence encoding CLH product may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of *CaMV* (Brisson *et al.*, *Nature* **310**:511-514, (1984)) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu *et al.*, *EMBO J.*, **6**:307-311, (1987)). Alternatively, plant promoters such as the small subunit of
20 RUBISCO (Coruzzi *et al.*, *EMBO J.* **3**:1671-1680, (1984); Broglie *et al.*, *Science* **224**:838-843, (1984)); or heat shock promoters (Winter J and Sinibaldi R.M., *Results Probl. Cell Differ.*, **17**:85-105, (1991)) may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobbs S. or
25 Murry L.E. (1992) in McGraw Hill Yearbook of Science and Technology, McGraw Hill, New York, N.Y., pp 191-196; or Weissbach and Weissbach (1988) *Methods for Plant Molecular Biology*, Academic Press, New York, N.Y., pp 421-463.

CLH product may also be expressed in an insect system. In one such
30 system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a

vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The CLH product coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of CLH coding sequence will render
5 the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which CLH protein is expressed (Smith *et al.*, *J. Virol.* 46:584, (1983); Engelhard, E.K. *et al.*, *Proc. Nat. Acad. Sci.* 91:3224-7, (1994)).

In mammalian host cells, a number of viral-based expression systems may
10 be utilized. In cases where an adenovirus is used as an expression vector, a CLH product coding sequence may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing CLH protein in infected host
15 cells (Logan and Shenk, *Proc. Natl. Acad. Sci.* 81:3655-59, (1984). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be required for efficient translation of a CLH protein coding sequence. These signals include the ATG initiation codon
20 and adjacent sequences. In cases where CLH product coding sequence, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon
25 must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf, D. *et al.*,

(1994) *Results Probl. Cell Differ.* **20**:125-62. (1994) Bittner et al., *Methods in Enzymol* **153**:516-544. (1987)).

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., and Battey, I. (1986) *Basic Methods in Molecular Biology*). Cell-free translation systems can also be employed to produce polypeptides using RNAs derived from the DNA constructs of the present invention.

A host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "pre-pro" form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express CLH product may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the

introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M., *et al.*, *Cell* 11:223-32, (1977)) and adenine phosphoribosyltransferase (Lowy I., *et al.*, *Cell* 22:817-23, (1980)) genes which can be employed in *tk*- or *aprt*- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, *dhfr* which confers resistance to methotrexate (Wigler M., *et al.*, *Proc. Natl. Acad. Sci.* 77:3567-70, (1980)); *npt*, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. *et al.*, *J. Mol. Biol.*, 150:1-14, (1981)) and *als* or *pat*, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman S.C. and R.C. Mulligan, *Proc. Natl. Acad. Sci.* 85:8047-51, (1988)). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate, GUS, and luciferase and its substrates, luciferin and ATP, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. *et al.*, *Methods Mol. Biol.*, 55:121-131, (1995)).

Host cells transformed with a nucleotide sequence encoding CLH product may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The product produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing nucleic acid sequences encoding CLH product can be designed with signal sequences which direct secretion of CLH product through a prokaryotic or eukaryotic cell membrane.

CLH product may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension affinity purification system (Immunex Corp. Seattle, Wash.). The inclusion of a protease-cleavable polypeptide linker sequence between the purification domain and CLH protein is useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising a CLH polypeptide fused to a polyhistidine region separated by an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography, as described in Porath, *et al.*, *Protein Expression and Purification*, **3**:263-281, (1992)) while the enterokinase cleavage site provides a means for isolating CLH polypeptide from the fusion protein. *pGEX* vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to ligand-agarose beads (e.g., glutathione-agarose in the case of GST-fusions) followed by elution in the presence of free ligand.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well known to those skilled in the art.

The CLH products can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

10

C. Diagnostic applications utilizing nucleic acid sequences

The nucleic acid sequences of the present invention may be used for a variety of diagnostic purposes. The nucleic acid sequences may be used to detect and quantitate expression of CLH in patient's cells, e.g. biopsied tissues, by
15 detecting the presence of mRNA coding for CLH product. Alternatively, the assay may be used to detect soluble CLH in the serum or blood. This assay typically involves obtaining total mRNA from the tissue or serum and contacting the mRNA with a nucleic acid probe. The probe is a nucleic acid molecule of at least 20 nucleotides, preferably 20-30 nucleotides, capable of specifically
20 hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding CLH under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of CLH. This assay can be used to distinguish between absence, presence, and excess expression of CLH product and to monitor levels of CLH expression during
25 therapeutic intervention.

The invention also contemplates the use of the nucleic acid sequences as a diagnostic for diseases resulting from inherited defective CLH sequences. These sequences can be detected by comparing the sequences of the defective (i.e., mutant) CLH coding region with that of a normal coding region. Association of
30 the sequence coding for mutant CLH product with abnormal CLH product

activity may be verified. In addition, sequences encoding mutant CLH products can be inserted into a suitable vector for expression in a functional assay system (e.g., colorimetric assay, complementation experiments in a CLH protein deficient strain of HEK293 cells) as yet another means to verify or identify mutations. Once mutant genes have been identified, one can then screen populations of interest for carriers of the mutant gene.

Individuals carrying mutations in the nucleic acid sequence of the present invention may be detected at the DNA level by a variety of techniques. Nucleic acids used for diagnosis may be obtained from a patient's cells, including but not limited to such as from blood, urine, saliva, placenta, tissue biopsy and autopsy material. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki, *et al.*, *Nature* **324**:163-166, (1986)) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complementary to the nucleic acid of the present invention can be used to identify and analyze mutations in the gene of the present invention. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype.

Point mutations can be identified by hybridizing amplified DNA to radiolabeled RNA of the invention or alternatively, radiolabeled antisense DNA sequences of the invention. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (e.g. Cotton, *et al.* *Proc. Natl. Acad. Sci. USA*, **85**:4397-4401, (1988)), or by differences in melting temperatures. "Molecular beacons" (Kostrikis L.G. *et al.*, *Science* **279**:1228-1229, (1998)), hairpin-shaped, single-stranded synthetic oligo-nucleotides containing probe sequences which are complementary to the nucleic acid of the present invention, may also be used to detect point mutations or other sequence changes as well as monitor expression levels of CLH product. Such diagnostics would be particularly useful for prenatal testing.

Another method for detecting mutations uses two DNA probes which are designed to hybridize to adjacent regions of a target, with abutting bases, where the region of known or suspected mutation(s) is at or near the abutting bases. The two probes may be joined at the abutting bases, e.g., in the presence of a
5 ligase enzyme, but only if both probes are correctly base paired in the region of probe junction. The presence or absence of mutations is then detectable by the presence or absence of ligated probe.

Also suitable for detecting mutations in the CLH product coding sequence are oligonucleotide array methods based on sequencing by hybridization (SBH),
10 as described, for example, in U.S. Patent No. 5,547,839. In a typical method, the DNA target analyte is hybridized with an array of oligonucleotides formed on a microchip. The sequence of the target can then be "*read*" from the pattern of target binding to the array.

15 D. Gene mapping utilizing nucleic acid sequences

The nucleic acid sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the
20 chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

25 Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 20-30 bp) from the CLH cDNA. Computer analysis of the 3' untranslated region is used to rapidly select primers that do not span more than one exon in the genomic DNA, which would complicate the amplification process. These primers are then used for PCR screening of somatic cell hybrids

containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

PCR mapping of somatic cell hybrids or using instead radiation hybrids are rapid procedures for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 50 or 60 bases. For a review of this technique, see Verma *et al.*, *Human Chromosomes: a Manual of Basic Techniques*, (1988) Pergamon Press, New York.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in the OMIM database (Center for Medical Genetics, Johns Hopkins University, Baltimore, MD and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD). The OMIM gene map presents the cytogenetic map location of disease genes and other expressed genes. The OMIM database provides information on diseases associated with the chromosomal location. Such associations include the results of linkage analysis mapped to this interval, and the correlation of translocations and other chromosomal aberrations in this area with the advent of various diseases associated with abnormal amounts or function of BMPs.

E. Therapeutic applications of nucleic acid sequences

Nucleic acid sequences of the invention may also be used for therapeutic purposes. Turning first to the second aspect of the invention (i.e. inhibition of expression of CLH), expression of CLH product may be modulated through antisense technology, which controls gene expression through hybridization of complementary nucleic acid sequences, i.e. antisense DNA or RNA, to the control, 5' or regulatory regions of the gene encoding CLH product. For example, the 5' coding portion of the nucleic acid sequence sequence which codes for the product of the present invention is used to design an antisense oligonucleotide of from about 10 to 40 base pairs in length. Oligonucleotides derived from the transcription CLHt site, e.g. between positions -10 and +10 from the CLHt site, are preferred. An antisense DNA oligonucleotide is designed to be complementary to a region of the nucleic acid sequence involved in transcription (Lee *et al.*, *Nucl. Acids, Res.*, 6:3073, (1979); Cooney *et al.*, *Science* 241:456, (1988); and Dervan *et al.*, *Science* 251:1360, (1991)), thereby preventing transcription and the production of the CLH products. An antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the CLH products (Okano *J. Neurochem.* 56:560, (1991)). The antisense constructs can be delivered to cells by procedures known in the art such that the antisense RNA or DNA may be expressed *in vivo*. The antisense may be antisense mRNA or DNA sequence capable of coding such antisense mRNA. The antisense mRNA or the DNA coding thereof can be complementary to the full sequence of nucleic acid sequences coding to the CLH protein or to a fragment of such a sequence which is sufficient to inhibit production of a protein product.

Turning now to the first aspect of the invention, i.e. expression of CLH, expression of CLH product may be increased by providing coding sequences for coding for said product under the control of suitable control elements ending its expression in the desired host.

The nucleic acid sequences of the invention may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.

The products of the invention as well as any activators and deactivators compounds (see below) which are polypeptides, may also be employed in accordance with the present invention by expression of such polypeptides *in vivo*, which is often referred to as "*gene therapy*." Cells from a patient may be engineered with a nucleic acid sequence (DNA or RNA) encoding a polypeptide *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention.

Similarly, cells may be engineered *in vivo* for expression of a polypeptide *in vivo* by procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells *in vivo* and expression of the polypeptide *in vivo*. These and other methods for administering a product of the present invention by such method should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells *in vivo* after combination with a suitable delivery vehicle.

Retroviruses from which the retroviral plasmid vectors mentioned above may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, adenovirus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the *PE501*, *PA317*, *psi-2*, *psi-AM*, *PA12*, *T19-14X*, *VT-19-17-H2*, *psi-CRE*, *psi-CRIP*, *GP-E-86*, *GP+envAm12*,
5 and *DAN* cell lines as described in Miller (*Human Gene Therapy*, Vol. 1, pg. 5-14, (1990)). The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO_4 precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and
10 then administered to a host.

The producer cell line generates infectious retroviral vector particles which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express the nucleic
15 acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

The genes introduced into cells may be placed under the control of
20 inducible promoters, such as the radiation-inducible Egr-1 promoter, (Maceri, H.J., *et al.*, *Cancer Res.*, 56(19):4311 (1996)), to stimulate CLH production or antisense inhibition in response to radiation, eg., radiation therapy for treating tumors.

25 **Example II. CLH product**

The substantially purified CLH product of the invention has been defined above as the product coded from the nucleic acid sequence of the invention. Preferably the amino acid sequence is an amino acid sequence having at least
70%, preferably at least 80% or 90% identity to the sequence identified as any
30 one of SEQ ID NO: 5 to SEQ ID NO: 8. The protein or polypeptide may be in

mature and or modified form, also as defined above. Also contemplated are protein fragments having at least 10 contiguous amino acid residues, preferably at least 10-20 residues, derived from the CLH product.

The sequence variations are preferably those that are considered conserved substitutions, as defined above. Thus, for example, a protein with a sequence having at least 80% sequence identity with the protein identified as any one of SEQ ID NO: 5 to SEQ ID NO: 8, preferably by utilizing conserved substitutions as defined above is also part of the invention. In a more specific embodiment, the protein has or contains the sequence identified as any one of SEQ ID NO: 5 to SEQ ID NO: 8. The CLH product may be (i) one in which one or more of the amino acid residues in a sequence listed above are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue), or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the CLH product is fused with another compound, such as a compound to increase the half-life of the protein (for example, polyethylene glycol (PEG)), or a moiety which serves as targeting means to direct the protein to its target tissue or target cell population (such as an antibody), or (iv) one in which additional amino acids are fused to the CLH product. Such fragments, variants and derivatives are deemed to be within the scope of those skilled in the art from the teachings herein.

A. Preparation of CLH product

Recombinant methods for producing and isolating the CLH product, and fragments of the protein are described above.

In addition to recombinant production, fragments and portions of CLH product may be produced by direct peptide synthesis using solid-phase techniques (cf. Stewart *et al.*, (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San Francisco; Merrifield J., *J. Am. Chem. Soc.*, 85:2149-2154, (1963)). In vitro peptide synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems

431.A Peptide Synthesizer (Perkin Elmer, Foster City, Calif.) in accordance with the instructions provided by the manufacturer. Fragments of CLH product may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

5

B. Therapeutic uses and compositions utilizing the CLH product

The CLH product of the invention is generally useful in treating diseases and disorders which are characterized by a lower than normal level of CLH expression, and or diseases which can be cured or ameliorated by raising the level
10 of the CLH product, even if the level is normal.

Typically these diseases are in CLH products or fragments and may be administered by any of a number of routes and methods designed to provide a consistent and predictable concentration of compound at the target organ or tissue. The product-containing compositions may be administered alone or in
15 combination with other agents, such as stabilizing compounds, and/or in combination with other pharmaceutical agents such as drugs or hormones.

CLH product-containing compositions may be administered by a number of routes including, but not limited to oral, intravenous, intramuscular, transdermal, subcutaneous, topical, sublingual, or rectal means as well as by nasal
20 application. CLH product-containing compositions may also be administered via liposomes. Such administration routes and appropriate formulations are generally known to those of skill in the art.

The product can be given via intravenous or intraperitoneal injection. Similarly, the product may be injected to other localized regions of the body. The
25 product may also be administered via nasal insufflation. Enterai administration is also possible. For such administration, the product should be formulated into an appropriate capsule or elixir for oral administration, or into a suppository for rectal administration.

The foregoing exemplary administration modes will likely require that the
30 product be formulated into an appropriate carrier, including ointments, gels,

suppositories. Appropriate formulations are well known to persons skilled in the art.

Dosage of the product will vary, depending upon the potency and therapeutic index of the particular polypeptide selected.

5 A therapeutic composition for use in the treatment method can include the product in a sterile injectable solution, the polypeptide in an oral delivery vehicle, the product in an aerosol suitable for nasal administration, or the product in a nebulized form, all prepared according to well known methods. Such compositions comprise a therapeutically effective amount of the compound, and a
10 pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose water, glycerol, ethanol, and combinations thereof. The product of the invention may also be used to modulate endothelial differentiation and proliferation as well as to modulate apoptosis, either *ex vivo* or *in vitro*, for example, in cell cultures.

15

Example III. Screening methods for activators and deactivators (inhibitors)

The present invention also includes an assay for identifying molecules, such as synthetic drugs, antibodies, peptides, or other molecules, which have a
20 modulating effect on the activity of the CLH product, e.g. activators or deactivators of the CLH product of the present invention. Such an assay comprises the steps of providing an CLH product encoded by the nucleic acid sequences of the present invention and determining its physiological activity on the target in the presence and absence of one or more candidate molecules to
25 determine the candidate molecules. Those molecules which are modulating effect on the activity of the CLH product are selected as likely candidates for activators and deactivators.

CLH product, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of
30 drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support, borne on a cell membrane or located

intracellularly. The formation of binding complexes, between CLH product and the agent being tested, may be measured. Alternatively, the activator or deactivator may work by serving as agonist or antagonist, respectively, of the CLH receptor and their effect may be determined in connection with the receptor.

5 Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the CLH product is described in detail by Geysen in PCT Application WO 84/03564, published on Sep. 13, 1984. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins
10 or some other surface. The peptide test compounds are reacted with the full CLH product or with fragments of CLH product and washed. Bound CLH product is then detected by methods well known in the art. Substantially purified CLH product can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to
15 capture the peptide and immobilize it on a solid support.

Antibodies to the CLH product, as described in Example IV below, may also be used in screening assays according to methods well known in the art. For example, a "*sandwich*" assay may be performed, in which an anti-CLH antibody is affixed to a solid surface such as a microtiter plate and CLH product is added.
20 Such an assay can be used to capture compounds which bind to the CLH product. Alternatively, such an assay may be used to measure the ability of compounds to influence with the binding of CLH product to the CLH receptor [I and then select those compounds which effect the binding.

25 **Example IV. Anti-CLH antibodies**

A. Synthesis

In still another aspect of the invention, the purified CLH product is used to produce anti-CLH antibodies which have diagnostic and therapeutic uses related to the activity, distribution, and expression of the CLH product, in particular
30 therapeutic applications in modulating the effect of CLH on BMP proteins.

Antibodies to CLH product may be generated by methods well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments and fragments produced by an Fab expression library. Antibodies, i.e., those which inhibit
5 dimer formation, are especially preferred for therapeutic use.

A fragment CLH product for antibody induction does not require biological activity but have to feature immunological activity; however, the protein fragment or oligopeptide must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five
10 amino acids, preferably at least 10 amino acids of the sequences specified in SEQ ID NO: 2. Preferably they should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of CLH protein amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and
15 antibody produced against the chimeric molecule. Procedures well known in the art can be used for the production of antibodies to CLH product.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with CLH product or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on
20 the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and
25 *Corynebacterium parvum* are potentially useful human adjuvants.

Monoclonal antibodies to CLH protein may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (*Nature* **256**:495-497, (1975)), the
30 human B-cell hybridoma technique (Kosbor *et al.*, *Immunol. Today* **4**:72, (1983);

Cote *et al.*, *Proc. Natl. Acad. Sci.* **80**:2026-2030, (1983)) and the EBV-hybridoma technique (Cole, *et al.*, *Mol. Cell Biol.* 62:109-120. (1984)).

Techniques developed for the production of "*chimeric antibodies*", the splicing of mouse antibody genes to human antibody genes to obtain a molecule
5 with appropriate antigen specificity and biological activity can also be used (Morrison *et al.*, *Proc. Natl. Acad. Sci.* **81**:6851-6855, (1984); Neuberger *et al.*, *Nature* **312**:604-608, (1984); Takeda *et al.*, *Nature* **314**:452-454, (1985)). Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single-chain antibodies
10 specific for the CLH protein.

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi *et al.* (*Proc. Natl. Acad. Sci.* **86**:3833-3837, 1989)), and Winter G and Milstein C., (*Nature*
15 **349**:293-299, (1991)).

Antibody fragments which contain specific binding sites for CLH protein may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the
20 disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse W.D. *et al.*, *Science* 256:1275-1281, (1989)).

25 **B. Diagnostic applications of antibodies**

A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the
formation of complexes between CLH product and its specific antibody and the
30 measurement of complex formation. A two-site, monoclonal-based immunoassay

utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific CLH product is preferred, but a competitive binding assay may also be employed. These assays are described in Maddox D.E., *et al.*, (*J. Exp. Med.* 158:1211, (1983)).

5 Antibodies which specifically bind CLH product are useful for the diagnosis of conditions or diseases characterized by over or under expression of CLH. Alternatively, such antibodies may be used in assays to monitor patients being treated with CLH product, its activators, or its deactivators. Diagnostic assays for CLH protein include methods utilizing the antibody and a label to
10 detect CLH product in human body fluids or extracts of cells or tissues. The products and antibodies of the present invention may be used with or without modification. Frequently, the proteins and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known in the art.

15 A variety of protocols for measuring CLH product, using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescent activated cell sorting (FACS). As noted above, a two-site, monoclonal-based immunoassay utilizing monoclonal
20 antibodies reactive to two non-interfering epitopes on CLH product is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, *et al.* (*supra*). Such protocols provide a basis for diagnosing altered or abnormal levels of CLH product expression. Normal or standard values for CLH product expression are established by combining body
25 or cell extracts taken from normal subjects, preferably human, with antibody to CLH product under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by various methods, preferably by photometric methods. Then, standard values obtained from normal samples may be compared with values obtained from

samples from subjects potentially affected by disease. Deviation between standard and subject values establishes the presence of disease state.

The antibody assays are useful to determine the level of CLH present in a body fluid sample, in order to determine whether it is being overexpressed or
5 underexpressed in the tissue, or as an indication of how CLH levels are responding to drug treatment.

Another alternative is to determine the presence and/or level of naturally occurring anti-CLH antibodies in a sample, such as blood or serum. Many times diseases are identified by detecting the presence or level of antibodies against a
10 specific product. For the detection of such naturally occurring anti-CLH antibodies, the sample may be contacted with the product of the invention, for example as depicted in any one of SEQ ID NO: 5 to SEQ ID NO: 8, or with an antigenic fragment thereof, and the presence or level of antibody-antigen complexes may be determined by methods well known in the art.

15

C. Therapeutic uses of antibodies

In addition to their diagnostic use the antibodies may have a therapeutical utility in blocking or decreasing the activity of the CLH product in pathological conditions where beneficial effect can be achieved by such a decrease.

20 The antibody employed is preferably a humanized monoclonal antibody, or a human Mab produced by known globulin-gene library methods. The antibody is administered typically as a sterile solution by IV injection, although other parenteral routes may be suitable. Typically, the antibody is administered in an amount between about 1-15 mg/kg body weight of the subject. Treatment is
25 continued, e.g., with dosing every 1-7 days, until a therapeutic improvement is seen.

Although the invention has been described with reference to specific methods and embodiments, it is appreciated that various modifications and changes may be made without departing from the invention.

CLAIMS:

1. An isolated nucleic acid sequence selected from the group consisting of:
 - (i) the nucleic acid sequence depicted in any one of SEQ ID NO: 1 to SEQ ID NO: 4;
 - 5 (ii) nucleic acid sequences having at least 70% identity with the sequence of (i); and
 - (iii) fragments of (i) or (ii) of at least 20 b.p.
2. A nucleic acid sequence according to Claim 1(ii) wherein the nucleic acid sequences have at least 80% identity with the sequence of Claim 1(i).
- 10 3. A nucleic acid sequence according to Claim 2, wherein the nucleic acid sequences have at least 90% identity.
4. An isolated nucleic acid sequence complementary to the nucleic acid sequence of Claim 1.
5. An amino acid sequence selected from the group consisting of:
 - 15 (i) an amino acid sequence coded by the isolated nucleic acid sequence of Claim 1;
 - (ii) fragments of the amino acid sequence of (i) having at least 10 amino acids;
 - (iii) analogues of the amino acid sequences of (i) or (ii) in which one or
 - 20 more amino acids has been added, deleted, replaced or chemically modified without substantially altering the biological activity of the parent amino acid sequence.
6. An amino acid sequence according to Claim 5, as depicted in any one of SEQ ID NO: 5 to SEQ ID NO: 8.
- 25 7. An isolated nucleic acid sequence coding for the amino acid sequence of Claim 5 or 6.
8. A purified antibody which binds specifically to the amino acid sequence of Claim 5 or 6.

9. An expression vector comprising the nucleic acid sequences of Claim 1 or 7 and control elements for the expression of the nucleic acid sequence in a suitable host.
10. An expression vector comprising the nucleic acid sequence of Claim 4, and
5 control elements for the expression of the nucleic acid sequence in a suitable host.
11. A host cell transfected by the expression vector of Claim 9 or 10.
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected from the group consisting of:
- (i) the expression vector of Claim 9; and
 - 10 (ii) the amino acid sequence of Claim 5 or 6.
13. A pharmaceutical composition according to Claim 12, for treatment of diseases which can be ameliorated, cured or prevented by raising the level of the Chordin-Like-Homolog (CLH).
14. A pharmaceutical composition comprising a pharmaceutically acceptable
15 carrier and as an active ingredient an agent selected from the group consisting of:
- (i) the nucleic acid sequence of Claim 4;
 - (ii) the expression vector of Claim 10; and
 - (iii) the purified antibody of Claim 8.
15. A pharmaceutical composition according to Claim 14, for treatment of
20 diseases which can be ameliorated or cured by decreasing the level of the CLH product.
16. A pharmaceutical composition according to Claim 12 or 14, for regulating the levels of bone morphogenic proteins (BMP).
17. A pharmaceutical composition according to Claim 16 for regulating the
25 levels of BMP-2 or BMP-4.
18. A method for detecting an CLH nucleic acid sequence in a biological sample, comprising the steps of:
- (a) - hybridizing to nucleic acid material of said biological sample a
nucleic acid sequence of Claim 1 or 4; and
 - 30 (b) detecting said hybridization complex;

wherein the presence of said hybridization complex correlates with the presence of an CLH nucleic acid sequence in the said biological sample.

19. A method according to Claim 18, wherein the nucleic acid material of said biological sample are mRNA transcripts.

20. A method according to Claim 18, where the nucleic acid sequence is present in a nucleic acid chip.

21. A method for identifying candidate compounds capable of binding to the CLH product and modulating its activity the method comprising:

(i) providing a protein or polypeptide comprising an amino acid sequence substantially as depicted in any one of SEQ ID NO: 5 to SEQ ID NO: 8, or a fragment of such a sequence;

(ii) comparing the physiological effect of the CLH product in the absence and presence of said candidate compound and selecting those compounds which show a significant effect on said physiological activity.

22. A method according to Claim 21, wherein the compound is an activator and the measured effect is increase in the physiological activity.

23. A method according to Claim 21, wherein the compound is an deactivator and the effect is decrease in the physiological activity.

24. An activator of the amino acid sequence of Claim 5 or 6.

25. An deactivator of the amino acid sequence of Claims 5 or 6.

26. A method for detecting CLH-product in a biological sample, comprising the steps of:

(a) contacting with said biological sample the antibody of Claim 8, thereby forming an antibody-antigen complex; and

(b) detecting said antibody-antigen complex

wherein the presence of said antibody-antigen complex correlates with the presence of CLH product in said biological sample.

27. A method for detecting anti-CLH antibodies in a biological sample comprising the steps of:

(a) contacting with said biological sample the antibody of Claim 5 or 6,
thereby forming an antibody-antigen complex; and


(b) detecting said antibody-antigen complex

wherein the presence of said antibody-antigen complex correlates with the
5 presence of anti-CLH antibody in said biological sample.

For the Applicants,

REINHOLD COHN AND PARTNERS

By:

A handwritten signature in black ink, consisting of several loops and a long horizontal stroke at the end.

SEQUENCE LISTING

<110> COMPUGEN LTD.

<120> NOVEL NUCLEIC ACID AND AMINO ACID SEQUENCES

<130> 102052-Compugen -N

<140>

<141>

<160> 3

<170> PatentIn Ver. 2.1

<210> 1

<211> 1261

<212> DNA

<213> Humanus

<400> 1

```

cagggagcca caaggcctga tgtactgcct gcgctgtacc tgctcagagg ggcgccatgt 60
gagttgttac cgcctccact gtccgcctgt ccactgcccc cagcctgtga cggagccaca 120
gcaatgctgt cccaagtgtg tggaacctca cactccctct ggactccggg ccccacccaa 180
gtcctgccag cacaacggga ccatgtacca acacggagag atcttcagtg cccatgagct 240
gttccccctc cgcctgcccc accagtgtgt cctctgcagc tgcacagagg gccagatcta 300
ctgcgggcct acaacctgcc ccgaaccagg ctgcccagca cccctccgcg tgccagactc 360
ctgctgccaa gcctgcaaag atgaggcaag tgagcaatcg gatgaagagg acagtgtgca 420
gtcgtcccat ggggtgagac atctcagga tccatgttcc agtgatgctg ggagaaagag 480
aggccccggg accccagccc ccactggcct cagcgccctt ctgagcttca tccctcgcca 540
cttcagaccc aaggagcag gcagcacaac tgtcaagatc gtcctgaagg agaaacatan 600
gaaagcctgt gtgcatggcg ggaagacgta ctcccacggg gaggtgtggc acccggcctt 660
ccgtgccttc ggcccttgcc catgcatcct atgcacctgt gaggatggcc gccaggactg 720
ccagcgtgtg acctgtccca cgaagtaccc ctgccgtcac cccgagaaaag tggctgggaa 780
gtgctgcaag atttgcccag aggacaaagc agaccctggc cacagtgaga tcagttctac 840
caggtgtccc aaggcaccgg gccgggtcct cgtccacaca tcggtatccc caagcccaga 900
caacctgcgt cgctttgccc tggaacacga ggcctcggac ttggtggaga tctacctctg 960
gaagctggta aaagatgagg aaactgaggc tcagagaggt gaagtacctg gcccaaggcc 1020
acacagccag aatttccact tgactcagat caagaaaagtc aggaagcaag acttccagaa 1080
agaggcacag cacttccgac tgctcgtctg cccccacgaa ggtcactgga acgtcttctt 1140
agcccagacc ctggagctga aggtcacggc cagtccagac aaagtgacca agacataaca 1200
aagacctaac agttgcagat atgagctgta taattgttgt tattatatat taataaataa 1260
gaagttgcat aaccatcaaa a                                     1281

```

<210> 2

<211> 1722

<212> DNA

<213> Humanus

<400> 2

```
accttccccc tttctttgat cgcctctccc ttctgctgga ccttcccttcg tctctccate 60
tctccctccc ttccccgcgt tctctttcca cttttctctt cttcccacct tagacctccc 120
ttcttgcccc cttttccctgc ccaccgctgc ttcttgcccc ttctccgacc ccgctctagc 180
agcagacctc ctgggggtcat gtgggttgat ctgtggcccc tgtgncctccg tgtccttttc 240
gtctcccgtc ctcccgactc cgctcccggg ccagcggcct gacctgggg aaaggatggg 300
tcccagaggcg agggctctct cctccttgct gggactcgcg ctgctctggg tccccctgga 360
ctcccacgct cgagccccgc cagacatggt ctgccttttc catgggaaga gatactcccc 420
cggcgagagc tggcaccctt acttgagacc acaggcctg atgtactgac tggcctgac 480
ctgctcagag ggcgcccatt tgagttgta ccgctccac tgtcgcctg tccactgccc 540
ccagcctgtg acggagccac agcaatgctg tcccagtggt gtggaacctc acactccctc 600
tggactccgg gccccaccaa agtctgcca gcacaacggg accatgtacc aacacggaga 660
gatcttcagt gcccatgagc tgttccccct ccgctgccc aaccagtgtg tctctgcag 720
ctgcacagag ggccagatct actgcggcct cacaacctgc cccgaaccag gctgcccagc 780
acccctcccg ctgccagact cctgctgcca agcctgcaaa gatgaggcaa gtgagcaatc 840
ggatgaagag gacagtgtgc agtcgctcca tggggtgaga catcctcagg atccatgttc 900
cagtgatgct gggagaaaga gaggcccggg caccacagcc cccactggcc tcagcgcccc 960
tctgagcttc atccctcgcc acttcagacc caaggagca ggcagcacia ctgtcaagat 1020
cgtcctgaag gagaaacata ngaaagcctg tgtgcatggc gggagacgt actcccacgg 1080
ggaggtgtgg cacccggcct tccgtgcctt cggcccttgc ccatgcatcc tatgcacctg 1140
tgaggatggc cgccaggact gccagcgtgt gacctgtccc acgaagtacc cctgccgtca 1200
ccccgagaaa gtggctggga agtgctgcaa gatttgcca gaggacaaag cagaccctgg 1260
ccacagtgag atcagttcta ccaggtgtcc caaggcaccg ggccgggtcc tcgtccacac 1320
atcggtatcc ccaagcccag acaacctgcg tcgctttgcc ctggaacacg aggcctcgga 1380
cttgggtggag atctacctct ggaagctggg aaaagatgag gaaactgagg ctgagagagg 1440
tgaagtacct ggcccaaggc cacacagcca gaatttccac ttgactcaga tcaagaaagt 1500
caggaagcaa gacttcagaa aagaggcaca gcacttccga ctgctcgctg gccccacga 1560
aggctactgg aacgtcttcc tagcccagac cctggagctg aaggtcacgg ccagtccaga 1620
caaagtgacc aagacataac aaagacctaa cagttgcaga tatgagctgt ataattgttg 1680
ttattatata ttaataaata agaagttgca taaccatcaa aa 1722
```

<210> 3

<211> 1515

<212> DNA

<213> Humanus

<400> 3

```
agaacagtgc ctggcnactga gaagtgctnc atgaaccctc attaaaatgc tggatgaact 60
aactcggggc ccactgagcg gaagctgagg ctgccggctt taccttcttg ctctggttgg 120
ggctggccca gacactgagg gggctggagg gctgtggtag aggtcatggg agggagggac 180
tcagtcagat gtaggtatca gagggacctc ttagttagct gataagggga atggctggca 240
aggcccaggg cagagcttgg tttaaatata aagctggggg caaatgcaaa atcaccagaa 300
aagtggcctt gttaatttca gcaagattc acatgaaacc tcattttctt cttcctcctg 360
cccctcccc actgtggaac ctcacactcc ctctggactc cgggccccac caaagtcctg 420
ccagcacaac gggaccatgt accaacacgg agagatcttc agtgcccatg agctgttccc 480
```

```

ctcccgccctg cccaaaccagt gtgtccctctg cagctgcaca gagggccaga tatactgcgg 640
cctccacaacc tgcctccgaac caggctgcgc agcaccctctc ccgctgcacg actccctgctg 680
ccaagccctgc aaagtatgagc caagtgcaca atcggatgaa gaggacagtg tgcagttcgt 660
ccatggggctg agacatccctc aggatccctg tcccagtgat gctgggagaa agagagggccc 720
gggcaccccca gcccccaactg gctccagcgc cctcttgagg ttcctccctc gccacttcag 760
accccaaggga gcaaggcagca caactgtcaa gctcgtccctg aaggagaaac atangaaagc 840
ctgtgtgcac ggccgggaaga cgtactccca cggggaaggcg tggcaccgcg ccttccgtgc 900
cttcgggccc tggccatgca tcttatgcac ctgtgaggat ggccgcacag actgcccagcg 960
tgtgacctgt cccacgaagt acccttgccg tcaccccgag aaagtggctg ggaagtgcct 1020
caagattctgc ccagaggaca aagcagaccc tggccacagt gagatcagtc ctaccaggtg 1080
tuccaaggca ccggggccggg tctctgtcca cacatcggta tccccaaagc cagacaaact 1140
ggctcgcctc gccctggaac acgaggcctc ggacttggtg gagatctacc tctggaaagt 1200
ggtaaaaagat gaggaaaactg aggcctagag aggtgaagta cctggcccaa ggcacacag 1260
ccagaatttc cacttgactc agatcaagaa agtcagggaag caagacttcc agaaagagggc 1320
acagcacttc cgaactgctc ctggccccc aagaaggcac tggaaagctc tctagccca 1380
gacctggag ctgaaggaca cggccagtc agacaaagtg accaagacat aacaaagacc 1440
taacagttgc agatatgagc tgtataattg ttgttattat atattaataa ataagaagtc 1500
gcataaccat caaaa 1515

```

<210> 4

<211> 1690

<212> DNA

<213> Humanus

<400> 4

```

tagnancgnc cgccaggggn tgnattcgcc cttactcann atagggntna acggccgccc 60
ggncaggctgc caaatggaca aataaaaagga aacaagcatg attgtnaggn cagaggaggg 120
tggnatttag tcagaagact ggtgctgtca tcgctgcntg gtgactgact tgctgtgtgg 180
ccntcagggtg taacttacct tctctgggcc tcatttgtct aatcataata attaacgttg 240
ataccatgat ataaatctgt acagcatttc actgcttgat tccctaactg ccctgtgaga 300
taagcgttaa ggctcagaga cagtggcatg ccagtggtg cacagtaagt gtgtggtaaa 360
gccgagattc aaactcagac cttctggccc cttgcctagg agagcatgcc cagttgtcta 420
gcagattctc ttttgctga gtggcccaga tgacatctct tttagagcta gaaagaagga 480
gaaatgagac agggctctttg ggctggagcc tcttgggact aacatggcac tggtcggttt 540
gccaggccca gacatgttct gccttttcca tgggaagaga tactcccccg gcgagagctg 600
gcacccctac ttggagccac aaggcctgat gtactgcctg cgctgtacct gctcagaggg 660
cgcccatgtg agttgttacc gcctccactg tccgcctgtc cactgcccc agcctgtgac 720
ggagccacag caatgctgtc ccaagtgtgt ggaacctcac actccctctg gactccgggc 780
cccaccaaag tcttgcacgc acaacgggac catgtacca cagggagaga tcttcagtgc 840
ccatgagctg tccccctccc gcctgcccac ccagtgtgtc ctctgcagct gcacagaggg 900
ccagatctac tgcggcctca caacctgccc cgaaccaggc tgcccagcac cctccccgt 960
gccagactcc tgctgccaa cctgcaaaga tgaggcaagt gagcaatcgg atgaagagga 1020
cagtgtgcag tcgctccatg gggtgagaca tctcaggat ccatgttcca gtgatgctgg 1080
gagaaagaga ggccggggca cccagcccc cactggcctc agcgccctc tgagcttcat 1140
ccctcgccac ttcagacca agggagcagg cagcacaact gtcaagatcg tctgaagga 1200
gaaacatang aaagcctgtg tgcattggcg gaagacgtac tcccacgggg aggtgtggca 1260
cccggccttc cgtgccttcg gcccttgccc atgcattcta tgcacctgtg aggatggccg 1320

```

ccaggactgc cagcgtgtga cctgtcccac gaagtacccc tgccgtcacc ccgagaaaagt 1380
 ggctgggaag tgctgcaaga ttgcccaga ggacaaagca gaccctggcc acagtgaat 1440
 cagttctacc aggtgtccca aggcaccggg cccggtcctc gtccacacat cggtatcccc 1500
 aagcccagac aacctgcgtc gctttgccct ggaacacgag gcctcggact tgggtggaat 1560
 ctacctctgg aagctggtaa aagatgagga aactgaggct cagagaggcg aagtacctgg 1620
 cccaaggcca cacagccaga atttccactt gactcagatc aagaaagtca ggaagcaaga 1680
 cttccagaaa gaggcacagc acttccgact gctcgtctggc ccccacgaag gtcactggaa 1740
 cgtcttctta gccagacccc tggagctgaa ggtcacggcc agtcacagaca aagtgaccaa 1800
 gacataacaa agaccttaaca gtgcagata tgagctgtat aattgttgtt attatatatt 1860
 aataaataag aagttgcata accatcaaaa 1890

<210> 5

<211> 398

<212> PRT

<213> Humanus

<400> 5

Arg Glu Pro Gln Gly Leu Met Tyr Cys Leu Arg Cys Thr Cys Ser Glu
 1 5 10 15

Gly Ala His Val Ser Cys Tyr Arg Leu His Cys Pro Pro Val His Cys
 20 25 30

Pro Gln Pro Val Thr Glu Pro Gln Gln Cys Cys Pro Lys Cys Val Glu
 35 40 45

Pro His Thr Pro Ser Gly Leu Arg Ala Pro Pro Lys Ser Cys Gln His
 50 55 60

Asn Gly Thr Met Tyr Gln His Gly Glu Ile Phe Ser Ala His Glu Leu
 65 70 75 80

Phe Pro Ser Arg Leu Pro Asn Gln Cys Val Leu Cys Ser Cys Thr Glu
 85 90 95

Gly Gln Ile Tyr Cys Gly Leu Thr Thr Cys Pro Glu Pro Gly Cys Pro
 100 105 110

Ala Pro Leu Pro Leu Pro Asp Ser Cys Cys Gln Ala Cys Lys Asp Glu
 115 120 125

Ala Ser Glu Gln Ser Asp Glu Glu Asp Ser Val Gln Ser Leu His Gly
 130 135 140

Val Arg His Pro Gln Asp Pro Cys Ser Ser Asp Ala Gly Arg Lys Arg
 145 150 155 160

Gly Pro Gly Thr Pro Ala Pro Thr Gly Leu Ser Ala Pro Leu Ser Phe
 165 170 175
 Ile Pro Arg His Phe Arg Pro Lys Gly Ala Gly Ser Thr Thr Val Lys
 180 185 190
 Ile Val Leu Lys Glu Lys His Xaa Lys Ala Cys Val His Gly Gly Lys
 195 200 205
 Thr Tyr Ser His Gly Glu Val Trp His Pro Ala Phe Arg Ala Phe Gly
 210 215 220
 Pro Cys Pro Cys Ile Leu Cys Thr Cys Glu Asp Gly Arg Gln Asp Cys
 225 230 235 240
 Gln Arg Val Thr Cys Pro Thr Lys Tyr Pro Cys Arg His Pro Glu Lys
 245 250 255
 Val Ala Gly Lys Cys Cys Lys Ile Cys Pro Glu Asp Lys Ala Asp Pro
 260 265 270
 Gly His Ser Glu Ile Ser Ser Thr Arg Cys Pro Lys Ala Pro Gly Arg
 275 280 285
 Val Leu Val His Thr Ser Val Ser Pro Ser Pro Asp Asn Leu Arg Arg
 290 295 300
 Phe Ala Leu Glu His Glu Ala Ser Asp Leu Val Glu Ile Tyr Leu Trp
 305 310 315 320
 Lys Leu Val Lys Asp Glu Glu Thr Glu Ala Gln Arg Gly Glu Val Pro
 325 330 335
 Gly Pro Arg Pro His Ser Gln Asn Phe His Leu Thr Gln Ile Lys Lys
 340 345 350
 Val Arg Lys Gln Asp Phe Gln Lys Glu Ala Gln His Phe Arg Leu Leu
 355 360 365
 Ala Gly Pro His Glu Gly His Trp Asn Val Phe Leu Ala Gln Thr Leu
 370 375 380
 Glu Leu Lys Val Thr Ala Ser Pro Asp Lys Val Thr Lys Thr
 385 390 395

<210> 6

<211> 539
 <212> PRT
 <213> Humanus

<400> 6

Ser	Pro	Leu	Pro	Ser	Ala	Gly	Pro	Ser	Phe	Val	Ser	Pro	Ser	Leu	Pro	1	5	10	15
Pro	Phe	Pro	Ala	Phe	Ser	Phe	His	Leu	Ser	Leu	Leu	Pro	Thr	Leu	Asp	20	25	30	
Leu	Pro	Ser	Cys	Pro	Pro	Phe	Leu	Pro	Thr	Ala	Ala	Ser	Trp	Pro	Phe	35	40	45	
Ser	Asp	Pro	Ala	Leu	Ala	Ala	Asp	Leu	Leu	Gly	Ser	Cys	Gly	Leu	Ile	50	55	60	
Cys	Gly	Pro	Cys	Xaa	Ser	Val	Ser	Phe	Ser	Ser	Pro	Val	Leu	Pro	Thr	65	70	75	80
Pro	Leu	Pro	Asp	Gln	Arg	Pro	Asp	Pro	Gly	Glu	Arg	Met	Val	Pro	Glu	85	90	95	
Val	Arg	Val	Leu	Ser	Ser	Leu	Leu	Gly	Leu	Ala	Leu	Leu	Trp	Phe	Pro	100	105	110	
Leu	Asp	Ser	His	Ala	Arg	Ala	Arg	Pro	Asp	Met	Phe	Cys	Leu	Phe	His	115	120	125	
Gly	Lys	Arg	Tyr	Ser	Pro	Gly	Glu	Ser	Trp	His	Pro	Tyr	Leu	Glu	Pro	130	135	140	
Gln	Gly	Leu	Met	Tyr	Cys	Leu	Arg	Cys	Thr	Cys	Ser	Glu	Gly	Ala	His	145	150	155	160
Val	Ser	Cys	Tyr	Arg	Leu	His	Cys	Pro	Pro	Val	His	Cys	Pro	Gln	Pro	165	170	175	
Val	Thr	Glu	Pro	Gln	Gln	Cys	Cys	Pro	Lys	Cys	Val	Glu	Pro	His	Thr	180	185	190	
Pro	Ser	Gly	Leu	Arg	Ala	Pro	Pro	Lys	Ser	Cys	Gln	His	Asn	Gly	Thr	195	200	205	
Met	Tyr	Gln	His	Gly	Glu	Ile	Phe	Ser	Ala	His	Glu	Leu	Phe	Pro	Ser	210	215	220	
Arg	Leu	Pro	Asn	Gln	Cys	Val	Leu	Cys	Ser	Cys	Thr	Glu	Gly	Gln	Ile				

225 230 235 240
 Tyr Cys Gly Leu Thr Thr Cys Pro Glu Pro Gly Cys Pro Ala Pro Leu
 245 250 255
 Pro Leu Pro Asp Ser Cys Cys Gln Ala Cys Lys Asp Glu Ala Ser Glu
 260 265 270
 Gln Ser Asp Glu Glu Asp Ser Val Gln Ser Leu His Gly Val Arg His
 275 280 285
 Pro Gln Asp Pro Cys Ser Ser Asp Ala Gly Arg Lys Arg Gly Pro Gly
 290 295 300
 Thr Pro Ala Pro Thr Gly Leu Ser Ala Pro Leu Ser Phe Ile Pro Arg
 305 310 315 320
 His Phe Arg Pro Lys Gly Ala Gly Ser Thr Thr Val Lys Ile Val Leu
 325 330 335
 Lys Glu Lys His Xaa Lys Ala Cys Val His Gly Gly Lys Thr Tyr Ser
 340 345 350
 His Gly Glu Val Trp His Pro Ala Phe Arg Ala Phe Gly Pro Cys Pro
 355 360 365
 Cys Ile Leu Cys Thr Cys Glu Asp Gly Arg Gln Asp Cys Gln Arg Val
 370 375 380
 Thr Cys Pro Thr Lys Tyr Pro Cys Arg His Pro Glu Lys Val Ala Gly
 385 390 395 400
 Lys Cys Cys Lys Ile Cys Pro Glu Asp Lys Ala Asp Pro Gly His Ser
 405 410 415
 Glu Ile Ser Ser Thr Arg Cys Pro Lys Ala Pro Gly Arg Val Leu Val
 420 425 430
 His Thr Ser Val Ser Pro Ser Pro Asp Asn Leu Arg Arg Phe Ala Leu
 435 440 445
 Glu His Glu Ala Ser Asp Leu Val Glu Ile Tyr Leu Trp Lys Leu Val
 450 455 460
 Lys Asp Glu Glu Thr Glu Ala Gln Arg Gly Glu Val Pro Gly Pro Arg
 465 470 475 480
 Pro His Ser Gln Asn Phe His Leu Thr Gln Ile Lys Lys Val Arg Lys

	485		490		495
Gln Asp Phe Gln Lys Glu Ala Gln His Phe Arg Leu Leu Ala Gly Pro					
	500		505		510
His Glu Gly His Trp Asn Val Phe Leu Ala Gln Thr Leu Glu Leu Lys					
	515		520		525
Val Thr Ala Ser Pro Asp Lys Val Thr Lys Thr					
	530		535		
<210> 7					
<211> 388					
<212> PRT					
<213> Humanus					
<400> 7					
Ile Ser Ser Trp Gly Gln Met Gln Asn His Gln Lys Ser Gly Leu Val					
1	5		10		15
Asn Phe Ser Lys Asp Ser His Glu Thr Ser Phe Ser Ser Ser Ser Cys					
	20		25		30
Pro Ser Pro Thr Val Glu Pro His Thr Pro Ser Gly Leu Arg Ala Pro					
	35		40		45
Pro Lys Ser Cys Gln His Asn Gly Thr Met Tyr Gln His Gly Glu Ile					
	50		55		60
Phe Ser Ala His Glu Leu Phe Pro Ser Arg Leu Pro Asn Gln Cys Val					
65		70		75	80
Leu Cys Ser Cys Thr Glu Gly Gln Ile Tyr Cys Gly Leu Thr Thr Cys					
	85		90		95
Pro Glu Pro Gly Cys Pro Ala Pro Leu Pro Leu Pro Asp Ser Cys Cys					
	100		105		110
Gln Ala Cys Lys Asp Glu Ala Ser Glu Gln Ser Asp Glu Glu Asp Ser					
	115		120		125
Val Gln Ser Leu His Gly Val Arg His Pro Gln Asp Pro Cys Ser Ser					
	130		135		140
Asp Ala Gly Arg Lys Arg Gly Pro Gly Thr Pro Ala Pro Thr Gly Leu					
145		150		155	160

Ser Ala Pro Leu Ser Phe Ile Pro Arg His Phe Arg Pro Lys Gly Ala
 165 170 175
 Gly Ser Thr Thr Val Lys Ile Val Leu Lys Glu Lys His Asa Lys Ala
 180 185 190
 Cys Val His Gly Gly Lys Thr Tyr Ser His Gly Glu Val Trp His Pro
 195 200 205
 Ala Phe Arg Ala Phe Gly Pro Cys Pro Cys Ile Leu Cys Thr Cys Glu
 210 215 220
 Asp Gly Arg Gln Asp Cys Gln Arg Val Thr Cys Pro Thr Lys Tyr Pro
 225 230 235 240
 Cys Arg His Pro Glu Lys Val Ala Gly Lys Cys Cys Lys Ile Cys Pro
 245 250 255
 Glu Asp Lys Ala Asp Pro Gly His Ser Glu Ile Ser Ser Thr Arg Cys
 260 265 270
 Pro Lys Ala Pro Gly Arg Val Leu Val His Thr Ser Val Ser Pro Ser
 275 280 285
 Pro Asp Asn Leu Arg Arg Phe Ala Leu Glu His Glu Ala Ser Asp Leu
 290 295 300
 Val Glu Ile Tyr Leu Trp Lys Leu Val Lys Asp Glu Glu Thr Glu Ala
 305 310 315 320
 Gln Arg Gly Glu Val Pro Gly Pro Arg Pro His Ser Gln Asn Phe His
 325 330 335
 Leu Thr Gln Ile Lys Lys Val Arg Lys Gln Asp Phe Gln Lys Glu Ala
 340 345 350
 Gln His Phe Arg Leu Leu Ala Gly Pro His Glu Gly His Trp Asn Val
 355 360 365
 Phe Leu Ala Gln Thr Leu Glu Leu Lys Val Thr Ala Ser Pro Asp Lys
 370 375 380
 Val Thr Lys Thr
 385

<210> 8
 <211> 439
 <212> PRT
 <213> Humanus

<400> 8
 Asp Arg Val Phe Gly Leu Glu Pro Pro Gly Thr Asn Met Ala Leu Val
 1 5 10 15
 Gly Leu Pro Gly Pro Asp Met Phe Cys Leu Phe His Gly Lys Arg Tyr
 20 25 30
 Ser Pro Gly Glu Ser Trp His Pro Tyr Leu Glu Pro Gln Gly Leu Met
 35 40 45
 Tyr Cys Leu Arg Cys Thr Cys Ser Glu Gly Ala His Val Ser Cys Tyr
 50 55 60
 Arg Leu His Cys Pro Pro Val His Cys Pro Gln Pro Val Thr Glu Pro
 65 70 75 80
 Gln Gln Cys Cys Pro Lys Cys Val Glu Pro His Thr Pro Ser Gly Leu
 85 90 95
 Arg Ala Pro Pro Lys Ser Cys Gln His Asn Gly Thr Met Tyr Gln His
 100 105 110
 Gly Glu Ile Phe Ser Ala His Glu Leu Phe Pro Ser Arg Leu Pro Asn
 115 120 125
 Gln Cys Val Leu Cys Ser Cys Thr Glu Gly Gln Ile Tyr Cys Gly Leu
 130 135 140
 Thr Thr Cys Pro Glu Pro Gly Cys Pro Ala Pro Leu Pro Leu Pro Asp
 145 150 155 160
 Ser Cys Cys Gln Ala Cys Lys Asp Glu Ala Ser Glu Gln Ser Asp Glu
 165 170 175
 Glu Asp Ser Val Gln Ser Leu His Gly Val Arg His Pro Gln Asp Pro
 180 185 190
 Cys Ser Ser Asp Ala Gly Arg Lys Arg Gly Pro Gly Thr Pro Ala Pro
 195 200 205
 Thr Gly Leu Ser Ala Pro Leu Ser Phe Ile Pro Arg His Phe Arg Pro
 210 215 220

Lys Gly Ala Gly Ser Thr Thr Val Lys Ile Val Leu Lys Glu Lys His
 225 230 235 240
 Asa Lys Ala Cys Val His Gly Gly Lys Thr Tyr Ser His Gly Glu Val
 245 250 255
 Trp His Pro Ala Phe Arg Ala Phe Gly Pro Cys Pro Cys Ile Leu Cys
 260 265 270
 Thr Cys Glu Asp Gly Arg Gln Asp Cys Gln Arg Val Thr Cys Pro Thr
 275 280 285
 Lys Tyr Pro Cys Arg His Pro Glu Lys Val Ala Gly Lys Cys Cys Lys
 290 295 300
 Ile Cys Pro Glu Asp Lys Ala Asp Pro Gly His Ser Glu Ile Ser Ser
 305 310 315 320
 Thr Arg Cys Pro Lys Ala Pro Gly Arg Val Leu Val His Thr Ser Val
 325 330 335
 Ser Pro Ser Pro Asp Asn Leu Arg Arg Phe Ala Leu Glu His Glu Ala
 340 345 350
 Ser Asp Leu Val Glu Ile Tyr Leu Trp Lys Leu Val Lys Asp Glu Glu
 355 360 365
 Thr Glu Ala Gln Arg Gly Glu Val Pro Gly Pro Arg Pro His Ser Gln
 370 375 380
 Asn Phe His Leu Thr Gln Ile Lys Lys Val Arg Lys Gln Asp Phe Gln
 385 390 395 400
 Lys Glu Ala Gln His Phe Arg Leu Leu Ala Gly Pro His Glu Gly His
 405 410 415
 Trp Asn Val Phe Leu Ala Gln Thr Leu Glu Leu Lys Val Thr Ala Ser
 420 425 430
 Pro Asp Lys Val Thr Lys Thr
 435

```

26  TGCCTGCGCTGTACCTGCTCAGAGGGGCCCATGTGAGTTGTTACCGCCT  75
    |||:::  ||| ||| |||:::  |||  |||  ::
711  CysPheThrCysThrCysGlnLysLysThr...ValIleCysAspProVa  726

76  CCACTGTCCGCCTGTCCACTGCCCCCCAGCCTGTGACGGAGCCACAGCAAT  125
    :  ||| |||  :::  |||  |||  ::: ||| |||
726  lMetCysProThrLeuSerCysThrHisThrValGlnProGluAspGlnC  743

126  GCTGTCCCAAGTGTGTGGAACCTCACACTCCCTCTGGACTCCGGGCC...  172
    ||| ||| |||  |||  |||  :::  |||
743  ysCysProIleCysGluGluLysLysGluSerLysGluThrAlaAlaVal  759

173  .....CCACCAAAGTCCTGCCAGCACAAACGGGACCATGTA  207
    |||::: |||::: |||::: |||:::
760  GluLysValGluGluAsnProGluGlyCysTyrPheGluGlyAspGlnLy  776

208  CCAACACGGAGAGATCTTCAGTGCCCATGAGCTGTTCCCTCCCGCCTGC  257
    ::: |||:::  :::  |||  :::  |||
776  sMetHisAlaProGlyThrThrTrpHisProPheValProPheGlyT  793

258  CCAACCAGTGTCTCTGCAGCTGC.....ACAGAGGCCAGATCTAC  301
    ::: |||::: |||::: |||::: |||::: |||:::
793  yrIleLysCysAlaValCysThrCysLysGlySerThrGlyGluValHis  809

```

Fig. 1

302 TGC GGCC TCACA ACCTG CCCC GAAC CAGG CTGCC CAGC ACCCT CCCC GCT 351
||| :::: ||||| ||| ||| :::
810 CysGluLysValThrCysProProLeuThrCysSerArgProIleArgAr 826
352 G... CCAGACTCCTGCTGCCAAGCCTGCAAAGATGAGGCAAGTGAGCAAT 398
||| :::: ||||| ||| ||| :::
826 gAsnProSerAspCysCysLysGluCysProProGluGluThrProProL 843
399 CGGATGAAGAGGACAGTGTGCAGTCGCTCCATGGGGTGAGACATCCTCAG 448
::::: ||||| ::||| :::
843 euGluAspGluGluMetMetGlnAla..... 851
449 GATCCATGTTCCAGTGATGCTGGGAGAAAGAGAGGCCCGGGCACCCAGC 498
|||||
852 AspGlyThr..... 854
499 CCCCACCTGGCCTCAGCGCCCTCTGAGCTTCATCCCTCGCCACTTCAGAC 548
854 854
549 CCAAGGAGCAGGCAGCACAACTGTCAAGATCGTCTGAAGGAGAAACAT 598
854 854

Fig. 1 (Cont.)

599 ANGAAAGCCTGTGTGCATGGCGGGAAGACGTACTCCACGGGAGGTGTG 648
 ::: ||| ||| :: |||:::|||| ||
855 ...ArgLeuCysLysPheGlyLysAsnTyrTyrGlnAsnSerGluHisTr 870
649 GCACCCGGCCTTCCGTGCCCTTCGGCCCTTGCCCATGCATCCTATGCACCT 698
 ||||||::: ||| ||||| ||| |
870 pHisProSerValProLeuValGlyGluMetLysCysIleThrCysTrpC 887
699 GTGAGGATGGCCCGCAGGACTGCCAGCGTGTGACCTGTCCCACGAAGTAC 748
 |::: ||| ||||| ||| |||||
887 ysAspHisGlyValThrLysCysGlnArgLysGlnCysProLeu...Leu 902
749 CCCTGCCGTACCCCGAGAAAGTGGCTGGGAAGTGCTGCAAGATTGCCCC 798
 ||||||:::| |::: ||||| ||| |||
903 SerCysArgAsnProIleArgThrGluGlyLysCysCysProGluCysIl 919

799 AGAGGAC 805
 |||||
919 eGluAsp 921

Fig. 1 (Cont.)

```
863 TCGCTCCATGGGGTGAGACATCCTCAGGATCCATGTTCCAGTGATGCTGG 912
    ||| ||| ::::: ||| ::::: |||
3 SerTyrHisArgSerHisTyrAspProProSerArgGlnAlaGlyGln 19

913 GAGAAAGAGAGCCCGGGCACCACCCAGCCCCACTGGCCTCAGCGCCCCCTC 962
    | :::: ||| |||||::: :::: |||
19 yLeuSerArgPheProGlyAlaArgSerHisArgGlyAlaLeu..... 33

963 TGAGCTTCATCCCTCGCCACTTCAGACCCCAAGGAGCAGCAGCACAACACT 1012
    :::: :::: |||:::~::~: |||
34 .....MetAspSerGlnGlnAlaSerGlyThrIle 43

1013 GTCAAGATCGTCCCTG.....AAGGAGAAACATANGAAAGCCTGTGTGCA 1056
    |||:::~: |||||::: |||:::~: |||||
44 ValGlnIleValIleAsnAsnLysHisLysHisGlyGlnValCysValse 60

1057 TGGCGGGAAGACGTACTCCACGGGGAGGTGTGGCACCCGGCC"TTCCCGTG 1106
    ::~: ||||| ||||| ||||| ||||| ||||| ::~: |||||
60 rAsnGlyLysThrTyrSerHisGlyGluSerTrpHisProAsnLeuArgA 77

1107 CCTTCGGCCCTTGCCCATGCATCCTATGCACCTGTGAGGATGGCCGCCAG 1156
    ||||| |||:::~: ||||| ||||| ||||| ::~: |||||
77 laPheGlyIleValGluCysValLeuCysThrCysAsnValThrLysGln 93
```

Fig.2a

```
1157 GACTGCCAGCGTGTGACCTGTCCACGAAGTACCCCTGCCGTCACCCCGA 1206
      ::::::::::: |||||:::|||||:::|||||:::
94 GluCysLysLysIleHisCysProAsnArgTyrProCysLysTyrProGlu 110

1207 GAAAGTGGCTGGGAAGTGCTGCAAGATTGCCCAGAGGACAAAGCAGAC. 1255
      :||||::: ||||||||||:::||||| |||||
110 nLysIleAspGlyLysCysCysLysValCysProGlyLysLysAlaLysG 127

1256 .....CCTGGCCACAGT...GAGATCAGTTCTACCAGGTGTCCCAAG 1294
      |||||:::|||| ::: |||||:::
127 luGluIleuProGlyGlnSerPheAspAsnLysGlyTyrPheCysGlyGlu 143

1295 GCACCGGGCCGGTCCCTCGTCCACACATCGGTA...TCCCCAAGCCCAGA 1341
      ::: |||::: ||||| ::: :::
144 Glu.....ThrMetProValTyrGluSerValPheMetGluAspGlyGl 158

1342 CAACCTGCGCTTTGCCCTGGAACACAGGCCCTCGGACTTGGTGGAGA 1391
      ::: |||:::||||| ||| |||||:
158 uThrThrArgLysIleAlaLeuGluThrGluArgProProGlnValGluV 175

1392 TCTACCTCTGGAAGCTGGTAANNNNNNNNNNNNNNNNNNNNNNNNNNNN 1441
      ::: ||| :::
175 alHisValTrpThrIle..... 180
```

Fig.2a (Cont.)

Fig.2a (Cont.)

```
100 TCTTCCACCTTAGACCTCCCTTCCTGCCCTCCTTTCCTGCCACCGCTG 149
    :::::|||||      |||      ||::: ||::: |||
429 ThrAlaHisLeuLeuGlyPro.....ProGlyThrProGlyProArg.. 442

150 CTTCCTGGCCCTTCTCCGACCCCGCTCTAGCAGACCTCCTGGGGTCA 199
    ||||||:::      :::||||::: ||||||:
443 .....ArgLeuLeuLysGlyPheTyrglySerGluAlaGlnGlyValV 457

200 TGTGGGTTGATCTGTGGCCCTGTGNCTCCGTCTTCCTTTCGTCTCCCGT 249
    ::      |||||| |||      |||||| |||
457 al...LysAspLeuGluProGluLeuLeuArgHisLeu..... 468

250 CCTCCCGACTCCGCTCCCGACCGCGCTGACCCCTGGGGAAGGATGG 299
    |||      |||      ||:::+++      ||
469 .....AlaLysGlyMetAlaSerLeuLeuIleThrThrLysGl 481

300 TTCC...CGAGGTGAG..... 312
    ||||      |||||||||
481 ySerProArgGlyGluLeuArgGlyGlnValHisIleAlaAsnGlnCysG 498
```

Fig. 2b

```

313  ....GGTCCTCTCCTCCTT.....GCTGGGACTTCGCGCT 342
      |||  |||  |||
498  luValGlyGlyLeuArgLeuAlaAlaGlyAlaGluGlyValArgAla 514
      |||  |||  |||
342  ..... 342
515  LeuGlyAlaProAspProAlaSerAlaAlaProProValValProGlyLe 531
343  ....GCTCTGGTTCCC.....CCTGGACTCCCCACGCTCGAGCCCCGCCCA 382
      |||||:::||||  |||||  |||  |||
531  uProAlaLeuAlaProAlaLysProGlyGlyPro.GlyArgProArgAsp 547
383  GACATGTTCTGCCCTTTCCATGGGAAGAGATACTCCCCCGCGAGAGCTG 432
      |||:::||||:::||||  |||  |||
548  ProAsnThrCysPheGluGlyGlnGlnArgProHisGlyAlaArgTr 564
433  GCACCCCTACTTGAGCCACAAGCCTGATGTACTGCCCTCGCTGTACCT 482
      |  |||  :::||||  |||  |||
564  pAlaProAsnTyrAspPro.....LeuCysSerLeuCysThrc 577

```

Fig. 2b (Cont.)

756 CCTGCCCCGAACCAAGCTGCCCCAGCACCCCTCCCGCTG...CCAGACTCC 802
|||||::: ::::| | | | | :::
675 lnCysProArgLeuAlaCysAlaGlnProValArgValAsnProThrAsp 691
803 TGCTGCCAAGCCTGCAAAAGATGAGGCAAGTGAGCAATCGGATGAAGAGGA 852
|||||::: | | |
692 CysCysLysGlnCys..... 696
853 CAGTGTGCAGTCGCTCCATGGGGTGAGACATCCTCAG.....GATCCAT 896
::: ::: | | | | | | | | | | | | | | |
697ProValGlySerGlyAlaHisProGlnLeuGlyAspProM 710
897 GTTCCAGTGCTGGGAGAAAGAGAGGCCCGGCGCCAGCCCCCCT 946
::: ::: | | | | |
710 etGlnAlaAsp.....GlyPro..... 715
947 GGCCTCAGCGCCCTCTGAGCTTCATCCCTCGCCCACTTCAGACCCAAGG 996
715 715
997 AGCAGGCAGCACAACTGTCAAGATCGTCTGAAGGAGAAACATANGAAAG 1046
:::
716ArgG 717

Fig. 2b (Cont.)

```
1047 CCTGTGTGCATGGCGGAAGACGTACTCCACGGGAGGTGTGGCACCCG 1096
      ::|||      ::|||:::      :::      :::      :::      |||||
717 lYcysArgPheAlaGlyGlnTrpPheProGluSerGlnSerTrpHisPro 733

1097 GCCTTCCGTGCCTTCGGCCCTTGCCCATGCATCCTATGCACCTGTGAGGA 1146
      :::      |||||      |||||      |||      |||
734 SerValProPheGlyGluMetSerCysIleThrCysArgCysGlyAl 750

1147 TGGCCGCCAGGACTGCCAGCGTGTGACCTGTCCACGAAGTACCCCTGCC 1196
      |||      |||:::||||      |||      |||
750 aGlyValProHisCysGluArgAspCysSerLeuProLeuSerCysG 767

1197 GTCACCCCGAGAAAGTGGCTGGGAAGTGCTGCAAGATTTC..... 1237
      :::      :::      :::      :::      :::      |||
767 lYSerGlyLysGlu.....SerArgCysCysSerArgCysThrAlaHis 781

1238 .....CCAGAGGACAAAGCAGACCCT 1258
      |||||      :::      |||||
782 ArgArgProAlaProGluThrArgThrAspPro 792
```

Fig. 2b (Cont.)

```
3  CTTCCCCCTTTCTTTGATCGCCTCTCC.....CTTCTGCTGGA 40
   |||||||      :::::   :::   |||   |||||
540 LeuProProValArgSerGlnAlaAlaGlyHisAlaTrpLeuSerLeuAs 556

41  CCTTCCTTCGTCCTCCATCTCTCCCTCCTT.....T 72
   |      |||||   :::::||||
556 pThrHisCysHisLeuHisTyrGluValLeuLeuAlaGlyLeuGlyGlyS 573

73  CCCCgcGTTCTCTTCCACCTTTCTCTTCTTCCcACCTTAGACCTCCCTT 122
   ||   :::::   |||      +++
573 erGluGlnGlyThrValThr..... 579

123 CCTGCCCTCCTTTCCCTGCCcACCGCTGCTTCCCTGGCCCTTCTCCGACCCC 172
   |||   |||   |||||   :::|||||::: |||
580 ...AlaHisLeuGlyProProGlyMetProGlyProGln.ArgLeuL 595

173 GCTCT.....AGCAGCAGACCTCCTGGGGTCATGTGGGTTGATCTG 213
   :::      :::||:::   |||||:::   |||||
595 euLysGlyPheTyrGlySerGluAlaGlnGlyValVal...LysAspLeu 610

214 TGGCCCCCTGTGNCTCCGT.....GT 233
   |||:::   |||||
611 GluProValLeuLeuArgHisLeuAlaGlnGlyThrAlaSerLeuLeuIl 627
```

Fig. 2c

```

234 CCTTTTCGTCTCCCGTCCCTCCCGACTCCGCTCCCGGACCA..... 273
      :
      ||| |||   ::|
627 eThrThrLysSerSerProArgGlyGluLeuArgGlyGlnValHisIleA 644

274 .....:::
      :
644 lSerGlnCysGluAlaGlyGlyLeuArgLeuAlaSerGluGlyValGln 660

280 TGACCCCTGGGAAAGGATGGTTCCCGAGGTGAGGGTCCCTCCTCCTTGC 329
      +++|||   ::| |||:::   ::| |||::: ||
661 MetProLeuAlaProAsnGlyGluAlaAlaThrSerProMetLeuProAl 677

330 TGGGACT...CGCGCTGCTCTGGTTCCCCCT.....GGACTCCCACGCT 370
      |||||   ||| |||||   ||| ||| :::
677 aGlyProGlyProGluAlaProValProAlaLysHisGlySerPro.Gly 693

371 CGAGCCCGCCAGACATGTTCTGCCTTTTCCATGGGAAGAGATACTCCCC 420
      ||| |||   |||::: |||::: |||::: |||:::
694 ArgProArgAspProAsnThrCysPhePheGluGlyGlnArgProHi 710

421 CGGCGAGAGCTGGCACCCCTACTTGGAGCCACAAGCCTGATGTACTGCC 470
      ||| ||| |||   ::| |||
710 sGlyAlaArgTrpAlaProAsnTyrAspPro.....LeuCysS 723

```

Fig. 2c (Cont.)

```

471 TCGGCTGTACCTGCTCAGAGGGCCCATGTGAGTTGTACC GCCTCCAC   520
      ||| ||||::: :: ||| ||| ::
723 erLeuCysIleCysGlnArgArgThr...ValIleCysAspProValVal   738
      ||||| | ||||:::||||| :||| |||||
521 TGTCCGCCCTGTCCACTGCCCCCAGCCTGTGACGGAGCCACAGCAATGCTG   570
      ||||| | ||||:::||||| :||| |||||
739 CysProProSerCysProHisProValGlnAlaLeuAspGlnCysCy       755
      ||||| | ||||:::||||| :||| |||||
571 TCCCAAGTGTGGAA..... CCTCACACTCCCCT'   599
      |||| ||| ||| ||| |||
755 sProValCysProGluLysGlnArgSerArgAspLeuProSerLeuProA    772
      ||||| | ||||:::||||| :||| |||||
600 CTGGACTCCGGGCCCCACC AAGTCCTGCCAGCACACGGGACCATTCTAC   649
      :: ||| :::::||| :||| |||
772 sn.....LeuGluProGlyGluGlyCysTyrPheAspGlyAspArgSer   786
      :: ||||| | ||||:::||||| :||| |||||
650 CAACACGGAGAGATCTTCAGTGCCCATGAGCTGTTCCTCCCGCCCTGCC    699
      ::::: ||| :: |||
787 TrpArgAlaAlaGlyThrArgTrpHisProValValProPheGlyLe     803
      ::::: ||||| | ||||:::||||| :||| |||||
700 CAACCAGTGTCTCTGCAGCTGC..... ACAGAGGCCAGATCTACT'   743
      ::|||::: ||||:::||||| :||| |||||
803 uilleLysCysAlaValCysThrCysLysGlyAlaThrGlyGluValHisC   820

```

Fig. 2c (Cont.)

744 GCGGCCTCACAACCTGCCCCGAACAGGCTGCCAGCACCCCTCCCGCTG 793
|| :::: |||||::: ::::| | | | | :::
820 ysGluLysValGlnCysProArgLeuAlaCysAlaGlnProValArgAla 836
794 ...CCAGACTCCTGCTGCCAAGCCTGCAAAAGATGAGGCAAGTGAGCAATC 840
||| ::::| | | | | ::: | | | |
837 AsnProThrAspCysCysLysGlnCys..... 845
841 GGATGAAGAGGACAGTGTGCAGTCGCTCCATGGGGTGAGACATCCTCAGG 890
845 845
891 ATCCATGTTCAGTGCTGGGAGAAAGAGAGGCCCGGGCACCCAGCC 940
| | | | | :::
846ProVal 847
941 CCCACTGGCCTCAGCGCCCTCTGAGCTTCATCCCTCGCCACTTCAGACC 990
:::| | | | | | | | | | :::
848 GlySerGlyThrAsnAlaLysLeuGlyAspProMetGlnAlaAspGlyPr 864
991 CAAGGAGCAGGACAACTGTCAAGATCGTCTGAAGGAGAAACATA 1040
| : : : | | | |
864 oArgGly..... 866

Fig. 2c (Cont.)

1041 NGAAAGCCTGTGTGCATGGCGGGAAGACGTACTCCACGGGAGGTGTGG 1090
||| ::|||::: ::::: |||
867CysArgPheAlaGlyGlnTrpPheProGluAsnGlnSerTrp 880

1091 CACCCGGCCTTCCGTGCCCTTCGGCCCTTGCCCATGCATCCTATGCACCTG 1140
|||||::: ||||| ||||| ||| ||
881 HisProSerValProPheGlyGluMetSerCysIleThrCysArgCy 897

1141 TGAGGATGGCCGCCAGGACTGCCAGCGTGTGACCTGTCCCACGAAGTACC 1190
| ||| |||::: ||| |||
897 sGlyAlaGlyValProHisCysGluArgAspAspCysSerProProLeuS 914

1191 CCTGCCGTACCCCGAGAAAGTGGCTGGGAAGTGCTGCAAGATTTC... 1237
||| ::::: ::::: |||||::: |||
914 erCysGlySerGlyLysGlu.....SerArgCysCysSerHisCysThr 928

1238CCAGAGGACAAAGCAGACCC 1257
||||| ::: :::
929 AlaGlnArgSerSerGluThrArgThrLeuProGluLeuGluLysGluAl 945

1258 TGGCCACAGT 1267
|||||
945 aGluHisSer 948

Fig. 2c (Cont.)

```
656 TCGCTCCATGGGGTGAGACATCCTCAGGATCCATGTTCCAGTGATGCTGG 705
    ||| ||| ::::: ||| ::: :::||
3 SerTyrHisArgSerHisTyrAspProProSerArgGlnAlaGlyGln 19

706 GAGAAAGAGAGCCCGGGCAGCCCCAGCCCCACTGGCCTCAGCGCCCTC 755
    | :::||| |||||::: ::: |||
19 yLeuSerArgPheProGlyAlaArgSerHisArgGlyAlaLeu..... 33

756 TGAGCTTCATCCCTCGCCACTTCAGACCCCAAGGAGCAGGCAGCACAACT 805
    ::: ::: |||:::||||
34 .....MetAspSerGlnGlnAlaSerGlyThrIle 43

806 GTCAAGATCGTCCTG.....AAGGAGAAACATANGAAAGCCTGTGTGCA 849
    |||:::|||||::: |||:::||||| :::|||||
44 ValGlnIleValIleAsnAsnLysHisLysHisGlyGlnValCysValSe 60

850 TGGCGGGAAGACGTACTCCACGGGGAGGTGTGGCACCCGGCCTTCCGTG 899
    :::||||| ||||| ||||| ||||| ||||| :::|||||
60 rAsnGlyLysThrTyrSerHisGlyGluSerTrpHisProAsnLeuArgA 77
```

Fig. 3a


```

900 CCTTCGGCCCTTGCCCATGCATCCTATGCACCTGTGAGGATGGCCGCCAG 949
      |||||      |||:::|||||:::      ::|||
77  laPheGlyIleValGluCysValLeuCysThrCysAsnValThrLysGln 93
950 GACTGCCAGCGTGTGACCTGTCCACGAAGTACCCCTGCCGTCACCCCGA 999
      ::|||:::  |||:::  ::|||:::  |||:::  ::|||:::
94  GluCysLysLysIleHisCysProAsnArgTyrProCysLysTyrProGln 110
1000 GAAAGTGGCTGGGAAGTGTGCAAGATTGCCCAGAGGACAAAGCAGAC. 1048
      :|||:::  ||||||  |||:::  |||  |||  |||  |||
110 nLysIleAspGlyLysCysCysLysValCysProGlyLysLysAlaLysG 127
1049 .....CCTGGCCACAGT...GAGATCAGTTCTACCAGGTGTCCCAAG 1087
      |||||:::  |||  :::  :::::  |||  :::
127 luGluLeuProGlyGlnSerPheAspAsnLysGlyTyrPheCysGlyGlu 143
1088 GCACCGGGCGGTCCTCGTCCACACATCGGTA...TCCCCAAGCCCGA 1134
      :::  |||:::  |||  |||  |||  :::  :::
144 Glu.....ThrMetProValTyrGluSerValPheMetGluAspGlyGln 158

```

Fig. 3a (Cont.)

Fig. 3a (Cont.)

```

368 CCCACTGTGGAACCTCACACTCCCTCTGGACTCCGGGCCCCA.....CC 411
    |||:::  |||  |||::: |||  |||  |||
532 proAlaLeuAlaProAlaLysProGlyGlyProGlyArgProArgAspPr 548
    |||::: |||  |||::: |||  |||  |||
412 AAAGTCCTGCCAGCACACGGGACCATGTACCAACACGGAGAGATCTTCA 461
    |::: |||  ::|||  ::  |||||  :::
548 oAsnThrCysPhePheGluGlyGlnGlnArgProHisGlyAlaArgTrpA 565
    |::: |||  ::|||  ::  |||||  |||
462 GTGCCCATGAGCTGTTCCTCCCTCCCGCCTGCCCAACCAG.....TGT 502
    ::  |||  |||||  |||  |||
565 la.....ProAsnTyrAspProLeuCys 572
    |||||::: |||  ::  |||  ::: |||
503 GTCTCTGCAGCTGCACAGAGGGCCAGATCTACTGCGGCTCACAACCTG 552
    |||||::: |||  ::  |||  ::: |||
573 SerLeuCysThrCysGlnArgArgThrValIleCysAspProValValCy 589
    ||||  |||::: |||||  |||::  |||||::: |||||
553 CCCCGAACCAAGCTGCCAGCACCCCTCCCGCTGCCAGACTCCTGCTGCC 602
    ||||  |||::: |||||  |||::  |||||::: |||||
589 sProProSerCysProHisProValGlnAlaProAspGlnCysCysP 606
    ||||  |||::: |||||  |||::  |||||::: |||||
603 AAGCCTGCAAGATGAGGCAAGTGAGCAATCGGATGAAGAGGACACTGTG 652
    ::: |||  |||::: |||||  |||::: |||||
606 roValCys.....ProGluLysGlnAspVal 614

```

Fig. 3b

653 CAGTCGCTCCATGGGGTGAGACATCCTCAGGATCCA.....TGTTTC 693
 :::||||| ||||: ::: :::||||| |||
615 ArgAspLeuProGlyLeuProArgSerArgAspProGlyGluGlyCysTy 631

694 CAGTGATGCTGGGAGAAAG...AGAGGCCCGGGCACC..... 727
 ||||: ||||: ||||: ||||: |||||
631 rPheAspGlyAspArgSerTrpArgAlaAlaGlyThrArgTrpHisProV 648

728 ..CCAGCCCCCACTGGCCTC..... 745
 ||| |||||
648 alValProProPheGlyLeuIleLysCysAlaValCysThrCysLysGly 664

745 745

665 GlyThrGlyGluValHisCysGluLysValGlnCysProArgLeuAlaCy 681

746 .AGCGCCCCCTCTGAGCTTCATCCCTCGCCACTTC.....AGACCCA 785
 ::: ||||: |||
681 sAlaGlnProValArgValAsnProThrAspCysCysLysGlnCysProV 698

Fig. 3b (Cont.)

```

786 AGGAGCAGGCAGC...ACAACTGTCAAGATCGTCTGAAGGAGAAACAT 832
      |||:::||||:::      ::      :::::
698 aIGlySerGlyAlaHisProGlnLeuGlyAspProMetGlnAlaAspGly 714
      833 ANGAAAGCCTGTGTGCATGGCGGAAGACGTACTCCACGGGAGGTGTG 882
      :::::||||      ::|||:::      ::      :::::  ||
715 ProArgGlyCysArgPheAlaGlyGlnTrpPheProGluSerGlnSerTr 731
      883 GCACCCGGCCTTCCGTGCCTTCGGCCCTTGCCCATGCATCCTATGCACCT 932
      |||||||:::      ||||||      |||||      |||      |
731 pHisProSerValProProPheGlyGluMetSerCysIleThrCysArgC 748
      933 GTGAGGATGGCCGCCAGGACTGCCAGCGTGTGACCTGTCCCACGAAGTAC 982
      ||      |||      |||:::||||      |||
748 ysGlyAlaGlyValProHisCysGluArgAspAspCysSerLeuProLeu 764
      983 CCTGCCGTCACCCCGAGAAAGTGGCTGGGAAGTGCTGCAAGATTTC.. 1030
      |||      :::::      :::::|||||:::      |||
765 SerCysGlySerGlyLysGlu.....SerArgCysCysSerArgCysTh 779
      1031 .....CCAGAGGACAAAGCAGACCCT 1051
      ||||||      :::::|||||
779 rAlaHisArgArgProAlaProGluThrArgThrAspPro 792

```

Fig. 3b (Cont.)

```
1031 TCGCTCCATGGGGTGAGACATCCTCAGGATCCATGTTCCAGTGATGCTGG 1080
    ||| ||| ::::: ||| ::|
3 SerTyrHisArgSerHisTyrAspProProSerArgGlnAlaGlyG1 19

1081 GAGAAAGAGAGGCCCGGCACCCAGCCCCCAGCTGGCCTCAGCGCCCTC 1130
    | ::||| |||||::: ::| |||
19 yLeuSerArgPheProGlyAlaArgSerHisArgGlyAlaLeu..... 33

1131 TGAGCTTCATCCCTCGCCCACTTCAGACCCCAAGGAGCAGCAGCACT 1180
    ::: ::| |||:::|
34 .....MetAspSerGlnGlnAlaSerGlyThrIle 43

1181 GTCAAGATCGTCCTG.....AAGGAGAAACATANGAAAGCCTGTGTGCA 1224
    |||:::|||||::| |||:::||||| :::|
44 ValGlnIleValIleAsnAsnLysHisLysHisGlyGlnValCysValSe 60

1225 TGGCGGGAAGACGTACTCCACGGGAGGTGTGGCACCCGGCCTTCCGTG 1274
    :::||||| ||||| ||||| ||||| :::|
60 rAsnGlyLysThrTyrSerHisGlyGluSerTrpHisProAsnLeuArgA 77
```

Fig. 4a

```
1275 CCTTCGGCCCTTGCCCATGCATCCTATGCACCTGTGAGGATGGCCGCCAG 1324
      |||||
      |||:::|||||:::
77  laPheGlyIleValGluCysValLeuCysThrCysAsnValThrLysGln 93

1325 GACTGCCAGCGTGTGACCTGTCCACGAAGTACCCCTGCCGTACCCCGA 1374
      ::|||:::
      |||||:::|||||:::|||||:::
94  GluCysLysLysIleHisCysProAsnArgTyrProCysLysTyrProGlu 110

1375 GAAAGTGGCTGGGAAGTGCTGCAAGATTGCCCCAGAGGACAAAGCAGAC. 1423
      :|||:::
      |||||:::|||||:::|||||
110 nLysIleAspGlyLysCysCysLysValCysProGlyLysLysAlaLysG 127

1424 .....CCTGGCCACAGT...GAGATCAGTTCTACCAGGTGTCCAAG 1462
      |||||:::|||| ::: ::::: ||| :::
127 luGluLeuProGlyGlnSerPheAspAsnLysGlyTyrPheCysGlyGlu 143

1463 GCACCGGGCGGTCCCTCGTCCACACATCGGTA...TCCCCAAGCCCAGA 1509
      ::: |||::: |||||
      ::: :::
144 Glu.....ThrMetProValTyrGluSerValPheMetGluAspGlyGlu 158
```

Fig. 4a (Cont.)

1510 CAACCTGCGTCGCTTTGCCCTTGAAACACGAGGCCCTCGGACTTGGTGGAGA 1559
 ::: |||:::||||| ||| |||||
158 uThrThrArgLysIleAlaLeuGluThrGluArgProProGlnValGluV 175

1560 TCTACCTCTGGAAGCTGGTAAANNNNNNNNNNNNNNNNNNNNNNNNNNNNN 1609
 :::||||| :::
175 alHisValTrpThrIle..... 180

1610 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNCAGAAATTCCACTTGACTCAGAT 1659
 ||||:||||| ||
181ArgLysGlyIleLeuGlnHisPheHis.....Il 190

1660 CAAGAAAGTCAGGAAGCAAGACTTCCAGAAAGAGGCACAGCACTTCCGAC 1709
 |:::||||::: |||::: ||| |||||:::|
190 eGluLysIleSerLysArgMetPheGlu...GluLeuProHisPheLysL 206

1710 TGC'TCGCTGGCCCCACGAAGTCACTGGAACGTCTTCTAGCCCAGACC 1759
 |:::||||: ::::||||:|:::|:::|
206 euValThrArgThrThrLeuSerGlnTrpLysIlePheThrGluGlyGlu 222

Fig. 4a (Cont.)

```
1760 CTGGAGCTGAAGGTCACGGCCAGTCCAGACAAAGTGACCAAGACATAACA 1809
      :::::::::::      ::::|||      +++
223  AlaGlnIleSerGlnMetCysSer..... 230

1810 AAGACCTAACAGTTGCAGATATGAGCTGTATAAATTGTTGTTATTATATAT 1859
      ::  |||||  |||||  ::::  ::::
231  ....SerArgValCysArgThrGluLeuGluAspLeuValLysValLeuT 246

1860 TAATAAAATAAGAAAGTTGCATAAACCAT 1885
      :::::::::::      ::::|||
246  yrLeuGluArgSerGluLysGlyHis 254
```

Fig. 4a (Cont.)

Fig. 4b

1033 GCTCCATGGGTGAGACATCCTCAGGATCCATGTTCCAGTGATCCTGGGA 1082
851 a.....
1083 GAAAGAGGCCCGGCACCCAGCCCCCACTGGCCTCAGCGCCCTCTG 1132
852AspGlyThr.....
1133 AGCTTCATCCCTCGCCACTTCAGACCCAAGGAGCAGGCACAACTGT 1182
854
1183 CAAGATCGTCTGAAGGAGAAACATANGAAAGCCTGTGTGCATGCGGGA 1232
855ArgLeuCysLysPheGlyLysA 862
1233 AGACGTACTCCACGGGAGGTGTGGCACCCGGCCTTCCGTGCCCTTCGGC 1282
862 snTyrTyrGlnAsnSerGluHisTrpHisProSerValProLeuValGly 878

Fig. 4b (Cont.)

1283 CCTTGCCCATGCATCCTATGCACCTGTGAGGATGCCGCCAGGACTGCCA 1332
||||| ||| |||::: ||| |||||
879 GluMetLysCysIleThrCysTrpCysAspHisGlyValThrLysCysGl 895
1333 GCGTGTGACCTGTCCACGAAGTACCCCTGCCCGTCACCCCGAGAAAGTGG 1382
||||| ||||| |||||::: ||| :::::
895 nArgLysGlnCysProLeu...LeuSerCysArgAsnProIleArgThrG 911
1383 CTGGGAAGTGCTGCAAGATTGCCCCAGAGGAC 1414
||||| ||||| ||||| |||||
911 luGlyLysCysCysProGluCysIleGluAsp

Fig. 4b (Cont.)

560 TGCCTTTTCCATGGGAAGAGATACTCCCCCGCGAGAGCTGGCACCCCTA 609
||| |||:::||||::: ::|::: ||| |||
693 CysSerPheGluGlyGlnLeuArgAlaHisGlySerArgTrpAlaProAs 709
610 CTTGGAGCCACAAGGCCTGATGTACTGCCTGCGCTGTACCTGCTCAGAGG 659
::: ::| ||| |||::: |||::: |||::: :::
709 pTyAspArgLys.....CysSerValCysSerCysGlnLysA 722
660 GCGCCCATGTGAGTTGTTACCGCCTCCACTGTCCGCCCTGTCCACTGCCCC 709
::: ||| ||| ::| ||| ||| |||::: ||| |||
722 rgThr...ValIleCysAspProIleValCysProProLeuAsnCysSer 737
710 CAGCCTGTGACGGAGCCACAGCAATGCTGTCCCAAGTGTGTGGAACCTCA 759
||||||| |||::: ||| ||| ||| ||| ||| |||
738 GlnProValHisLeuProAspGlnCysCysProValCysGluGluLysLy 754
760 CACTCCCTCTGGACTCCGGGCCCCACCAAGTCCTGCCAGCACACGGGA 809
::: ::| ||| ::: ::: ::: |||
754 sGluMetArgGluValLysLysProGluArgAlaArgThrSerGluGlyC 771

Fig. 4c

810 CCATGTACCAACACGAGAGATCTTCAGTGCC.....CAT 844
 ::: ::: :::
771 ysPhePheAspGlyAspArgSerTrpLysAlaAlaGlyThrArgTrpHis 787
 ::: ::: :::
845 GAGCTGTTCCCTCCCGCCTGCCCAACCAAGTGTGTCTCTGCAGCTGC.. 892
 ::: ::: :::
788 ProPheValProProPheGlyLeuIleLysCysAlaIleCysThrCysLy 804
 ::: ::: :::
893ACAGAGGGCCAGATCTACTGCGGCCCTCACAACCTGCCCCGAACCAAG 938
 ::: ::: :::
804 sGlySerThrGlyGluValHisCysGluLysValThrCysProLysLeuS 821
 ::: ::: :::
939 GCTGCCCAGCACCCCTCCCGCTG...CCAGACTCCTGCTGCCAAGCCTGC 985
 ::: ::: :::
821 erCysThrAsnProIleArgAlaAsnProSerAspCysCysLysGlnCys 837
 ::: ::: :::
986 AAAGATGAGGCAAGTGAGCAATCGGATGAAGAGGACAGTGTGCAGTCGCT 1035
 ::: ::: :::
838 ProValGluGluArgSerProMetGluLeuAlaAspSerMetGlnSer.. 853

Fig. 4c (Cont.)

• • •

1036 CCATGGGTGAGACATCCTCAGGATCCATGTTCCAGTGATGCTGGGAGAA 1085
853 853
1086 AGAGAGCCCGGGCACCCAGCCCCACTGGCCTCAGCGCCCTCTGAGC 1135
853 853
1136 TTCATCCCTCGCCACTTCAGACCCAAAGGAGCAGGCAGCACAACTGTCAA 1185
|||||
854 AspGlyAlaGlySer..... 858
1186 GATCGTCC'TGAAGGAGAAACATANGAAAGCCTGTGTGCATGGCGGGAAGA 1235
||| ||| CysArgPheGlyArgHist 865
859
1236 CGTACTCCACGGGAGGTGTGGCACCCGGCCTTCCGTGCCCTTCGGCCCT 1285
||| ::| ||| |||||::: |||||
865 rpTyrProAsnHisGluArgTrpHisProThrValProProPheGlyGlu 881
1286 TGCCCATGCATCCTATGCACCTGTGAGGATGGC.....CG 1320
|||::: ||||| ||| ::| |||
882 MetLysCysValThrCysThrCysAlaGluGlyIleThrGlnCysArgAr 898

Fig. 4c (Cont.)

```
1321 CCAGGACTGCCAGCGTGTGACCTGTCCACGAAGTACCCCTGCCGTCACC 1370
      |||||:::||||      :::|||||  |||
898 gGlnGluCysThrGlyThrThrCysGlyThr..... 908

1371 CCGAGAAAGTGGCTGGGAAGTGCTGCAAGATTGCCCCAGAGGACAAAGCA 1420
      :::      :::|||||  |||  :::  :::
909 ..GlySerLysArgAspArgCysCysThrLysCysLysAspAlaAsnGln 924
      |
1421 GACCCCTGGCCACAGT...GAGATCAGTTCTACCAGGTGTCCC 1459
      |||  :::::  :::  :::::|||||  |||
925 AspGluAspGluLysValLysSerAspGluThrArgThrPro 938
```

Fig. 4c (Cont.)

. . .

536 GGTTTGGCCAGGCCAGACATGTTCTGCCCTTTCCATGGGAAGAGATACTC 585
 ||| ||| |||:::||||:::||||:::|
543 GlyArgProArgAspProAsnThrCysPheGluGlyGlnGluArgPr 559
586 CCCCCGGGAGAGCTGGCACCCCTACTTGGAGCCACAAGGCCCTGATGTACT 635
 ||| ||| ||| ||| :::|
559 oHisGlyAlaArgTrpAlaProAsnTyrAspPro.....LeuC 572
636 GCCTGCGCTGTACCTGCTCAGAGGGCGCCCATGTGAGTTGTTACCGCCTC 685
 || |||||||||:::| ::: ||| ||| :::
572 ysSerLeuCysThrCysGlnArgArgThr...ValIleCysAspProVal 587
686 CACTGTCCGCTGTCCACTGCCCCAGCCCTGTGACGGAGCCACAGCAATG 735
 ||||||||| |||||||:::||||| |||:::|||||
588 ValCysProProSerCysProHisProValGlnAlaProAspGlnCy 604
736 CTGTCCCAAGTGTGTGGAA.....CCTCACACTC 764
 ||||||| ||| ||| ||| |
604 sCysProValCysProGluLysGlnAspValArgAspLeuProGlyIleuP 621

Fig. 4d

765 CCTCTGGACTCCGGGCCCCACCAAGTCTCTGCCAGCACACGGGACCATG 814
|| :: ||| ||| ::::: ||| ::::: |||
621 roArgSer...ArgAspProGlyGluGlyCysTyrPheAspGlyAspArg 636
815 TACCAACACGGAGAGATCTTCAGTGCCCATGAGCTGTCTCCCTCCCGCCT 864
::::: ||| :::: |||
637 SerTrpArgAlaAlaGlyThrArgTrpHisProValProPheGln 653
865 GCCCAACCAGTGTCCTCTGCAGCTGCACA.....GAGGGCCAGATCT 908
::: ||| ::::: ||| ::::: |||
653 yLeuIleLysCysAlaValCysThrCysLysGlyGlyThrGlyGluValH 670
909 ACTGCGGCCTCACAACTGCCCCGAACCAGGCTGCCAGCACCCCTCCCG 958
::: ||| :::: ||| ::::: ||| ::::: |||
670 isCysGluLysValGlnCysProArgLeuAlaCysAlaGlnProValArg 686
959 CTG...CCAGACTCCTGCTGCCAAGCCTGCAAAGATGAGGCAAGTGAGCA 1005
::: ||| :::: ||| ::::: |||
687 ValAsnProThrAspCysCysLysGlnCys..... 696

Fig. 4d (Cont.)

```

1006 ATCGGATGAAGAGGACAGTGTGCAGTCGCTCCATGGGGTGAGACATCCTC 1055
      ::      ::      |||||
697 .....ProValGlySerGlyAlaHisProG 705

1056 AG.....GATCCATGTTCCAGTGATGCTGGGAGAAAGAGAGGCCCGGC 1099
      ||      |||||      ::::|||      |||||
705 InLeuGlyAspProMetGlnAlaAsp.....GlyPro... 715

1100 ACCCCAGCCCCACTGGCCTCAGCGCCCCCTCTGAGCTTCATCCCTCGCCA 1149

715 ..... 715

1150 CTTCAGACCCAAAGGAGCAGGCAGCACAACTGTCAAGATCGTCTGAAGG 1199

715 ..... 715

1200 AGAAACATANGAAAGCCTGTGTGCATGGCGGGAAGACGTACTCCCACGGG 1249
      :::::||||      ::|||::      ::      :::::
716 .....ArgGlyCysArgPheAlaGlyGlnTrpPheProGluSer 728

1250 GAGGTGTGCACCCGGCCTTCCGTGCCCTTCGGCCCCCTTGCCCATGCATCCT 1299
      ::      |||||:::      |||||      |||||
729 GlnSerTrpHisProSerValProProPheGlyGluMetSerCysIleTh 745

```

Fig. 4d (Cont.)

1300 ATGCACCTGTGAGGATGGCCGCGCCAGGACTGCCAGCGTGTGACCTGTCCCA 1349
||| ||| ||| |||::||| |||
745 rCysArgCysGlyAlaGlyValProHisCysGluArgAspAspCysSerL 762
1350 CGAAGTACCCCTGCCGTCACCCCGAGAAAGTGGCTGGGAAGTGCTGCAAG 1399
||| ::::: ::::: |||::|||:::
762 euProLeuSerCysGlySerGlyLysGlu.....SerArgCysCysSer 776
1400 ATTTGC.....CCAGAGGACAAAGCAGACCCCT 1426
||| ||||| :::::||||||
777 ArgCysThrAlaHisArgArgProAlaProGluThrArgThrAspPro 792

Fig. 4d (Cont.)

.
.
.

chordin_ed7	SPLPSAGPSF	VSPSLPPFPA	FSFHLSSLPT	LDLPSCPPFL	P'AAASWPESD	
chordin_ed6TR_2	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
chordin_ed6TR_1	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
						100
chordin_ed7	PALAADLLGS	CGLICGPCXS	VSFSSPVLPT	PLPDQRDPFG	ERMVPEVRVI,	
chordin_ed6TR_2	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
chordin_ed6TR_1	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
						150
chordin_ed7	SSLGLALLW	FPLDSHARAR	PDMFCLFHGK	RYSPGESWHP	YLEPQGLMYC	
chordin_ed6TR_2	DRVFGLEPPG	TNMALVGLPG	PDMFCLFHGK	RYSPGESWHP	YLEPQGLMYC	
chordin_ed6TR_1	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
						200
chordin_ed7	LRCTCSEGAH	VSCYRLHCPP	VHCPQPVTE.	PQCCCPK.CV	EPHTPSGLRA	
chordin_ed6TR_2	LRCTCSEGAH	VSCYRLHCPP	VHCPQPVTE.	PQCCCPK.CV	EPHTPSGLRA	
chordin_ed6TR_1	~~~ISSWGQM	QNHQKSGLVN	FSKDSHETSF	SSSSCPSPTV	EPHTPSGLRA	

Fig. 5

chordin_ed7	201	PPKSCQHNGT	MYQHGEIFSA	HELFP SRLPN	QCVLCSCTEG	QIYCGLTTCP	250
chordin_ed6TR_2		PPKSCQHNGT	MYQHGEIFSA	HELFP SRLPN	QCVLCSCTEG	QIYCGLTTCP	
chordin_ed6TR_1		PPKSCQHNGT	MYQHGEIFSA	HELFP SRLPN	QCVLCSCTEG	QIYCGLTTCP	
chordin_ed7	251	EPGCPAPLPL	PDSCCQACKD	EASEQSD EED	SVQSLHGV RH	PQDPCSSDAG	300
chordin_ed6TR_2		EPGCPAPLPL	PDSCCQACKD	EASEQSD EED	SVQSLHGV RH	PQDPCSSDAG	
chordin_ed6TR_1		EPGCPAPLPL	PDSCCQACKD	EASEQSD EED	SVQSLHGV RH	PQDPCSSDAG	
chordin_ed7	301	RKRGP GTPAP	TGLSAPLSFI	PRHFRPKGAG	STTVKIIVLKE	KHXKACVHGG	350
chordin_ed6TR_2		RKRGP GTPAP	TGLSAPLSFI	PRHFRPKGAG	STTVKIIVLKE	KHXKACVHGG	
chordin_ed6TR_1		RKRGP GTPAP	TGLSAPLSFI	PRHFRPKGAG	STTVKIIVLKE	KHXKACVHGG	
chordin_ed7	351	KTYSHGEVWH	PAFRAFGPCP	CILCTCEDGR	QDCQRVTCPT	KYPCRHP EKV	400
chordin_ed6TR_2		KTYSHGEVWH	PAFRAFGPCP	CILCTCEDGR	QDCQRVTCPT	KYPCRHP EKV	
chordin_ed6TR_1		KTYSHGEVWH	PAFRAFGPCP	CILCTCEDGR	QDCQRVTCPT	KYPCRHP EKV	

Fig. 5 (Cont.)

chordin_ed7	401	AGKCCCKICPE	DKADPGHSEI	SSTRCPKAPG	RVLVHTSVSP	SPDNLRRFAL	450
chordin_ed6TR_2		AGKCCCKICPE	DKADPGHSEI	SSTRCPKAPG	RVLVHTSVSP	SPDNLRRFAL	
chordin_ed6TR_1		AGKCCCKICPE	DKADPGHSEI	SSTRCPKAPG	RVLVHTSVSP	SPDNLRRFAL	
chordin_ed7	451	EHEASDLVEI	YLWKLVKDEE	TEAQRGEVPG	PRPHSQNFIL	TQIKKVRKQD	500
chordin_ed6TR_2		EHEASDLVEI	YLWKLVKDEE	TEAQRGEVPG	PRPHSQNFIL	TQIKKVRKQD	
chordin_ed6TR_1		EHEASDLVEI	YLWKLVKDEE	TEAQRGEVPG	PRPHSQNFIL	TQIKKVRKQD	
chordin_ed7	501	FQKEAQHFRL	LAGPHEGHN	VFLAQTLELK	VTASPDKVTK	T*	542
chordin_ed6TR_2		FQKEAQHFRL	LAGPHEGHN	VFLAQTLELK	VTASPDKVTK	T*	
chordin_ed6TR_1		FQKEAQHFRL	LAGPHEGHN	VFLAQTLELK	VTASPDKVTK	T*	

Fig. 5 (Cont.)

THIS PAGE BLANK (USPTO)